Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: December 2010

Section 3 - Specific conditions

References

1. Birder L, Drake M. Neural control. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Paris: Health Publications Ltd; 2009:167–254.
2. Andrew J, Nathan PW. Lesions on the anterior frontal lobes and disturbances of micturition and defaecation. Brain 1964;87:233–62.
3. Ueki K. Disturbances of micturition observed in some patients with brain tumour. Neurologica Medica Chirugia 1960;2:25–33.
4. Maurice-Williams RS. Micturition symptoms in frontal tumours. J Neurol Neurosurg Psychiatry 1974;37:431–6.
5. Yamamoto S, Soma T, Hatayama T, Mori H, Yoshimura N. Neurogenic bladder induced by brain abscess. Br J Urol 1995;76:272.
6. Lang EW, Chesnut RM, Hennerici M. Urinary retention and space-occupying lesions of the frontal cortex. Eur Neurol 1996;36:43–7.
7. Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci 1996;137:47–56.
8. Laplane D, Degos JD, Baulac M, Gray F. Bilateral infarction of the anterior cingulate gyri and of the fornices. Report of a case. J Neurol Sci 1981;51:289–300.
9. Duffau H, Capelle L. Incontinence after brain glioma surgery: new insights into the cortical control of micturition and continence. Case report. J Neurosurg 2005;102:148–51.
10. Andrew J, Nathan PW, Spanos NC. Disturbances of micturition and defaecation due to aneurysms of anterior communicating or anterior cerebral arteries. J Neurosurg 1966;24:1–10.
11. Yamamoto T, Sakakibara R, Uchiyama T, et al. Lower urinary tract function in patients with pituitary adenoma compressing hypothalamus. J Neurol Neurosurg Psychiatry 2005;76:390–4.
12. Andrew J, Nathan PW. The cerebral control of micturition. Proc RSM 1965;58:553–5.
13. Yaguchi H, Soma H, Miyazaki Y, et al. A case of acute urinary retention caused by periaqueductal grey lesion. J Neurol Neurosurg Psychiatry 2004;75:1202–3.
14. Holman E. Difficult urination associated with intracranial tumours of the posterior fossa. A physiologic and clinical study. Arch Neurol Psychiat 1926;15:371–80.
15. Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance and the pontine tegmental lesion: urodynamic and MRI analyses of vascular cases. J Neurol Sci 1996;141:105–10.
16. Renier WO, Gabreels FJ. Evaluation of diagnosis and non-surgical therapy in 24 children with a pontine tumour. Neuropediatrics 1980;11:262–73.
17. Betts CD, Kapoor R, Fowler CJ. Pontine pathology and voiding dysfunction. Br J Urol 1992;70:100–2.
18. Manente G, Melchionda D, Uncini A. Urinary retention in bilateral pontine tumour: evidence for a pontine micturition centre in humans. J Neurol Neurosurg Psychiatry 1996;61:528–36.
19. Sakakibara R, Hattori T, Fukutake T, et al. Micturitional disturbance in herpetic brainstem encephalitis; contribution of the pontine micturition centre. J Neurol Neurosurg Psychiatry 1998;64:269–72.
20. Komiyama A, Kubota A, Hidai H. Urinary retention associated with a unilateral lesion in the dorsolateral tegmentum of the rostral pons. J Neurol Neurosurg Psychiatry 1998;65:953–4.
21. Weber J, Delangre T, Hannequin D, Beuret-Blanquart F, Denis P. Anorectal manometric anomalies in seven patients with frontal lobe brain damage. Dig Dis Sci 1990;35:225–30.
22. Weber J, Denis P, Mihout B, et al. Effect of brain-stem lesion on colonic and anorectal motility. Study of three patients. Dig Dis Sci 1985;30:419–25.
23. Baird AD, Wilson SJ, Bladin PF, Saling MM, Reutens DC. Neurological control of human sexual behaviour: insights from lesion studies. J Neurol Neurosurg Psychiatry 2007;78:1042–9.
24. Levine J, Albert H. Sexual behavior after lobotomy. J Nerv Ment Dis 1951;113:332–41.
25. Williamson PD, Spencer DD, Spencer SS, Novelly RA, Mattson RH. Complex partial seizures of frontal lobe origin. Ann Neurol 1985;18:497–504.
26. Toone BK. Sex, sexual seizure and the female with epilepsy. In: Trimble MR, ed. Women and epilepsy. Chichester: Wiley; 1991:201–6.
27. Bancaud J, Favel P, Bonis A, et al. Paroxysmal sexual manifestations and temporal lobe epilepsy. Clinical, EEG and SEEG study of a case of epilepsy of tumoral origin. Rev Neurol (Paris) 1970;123:217–30.
28. Gastaut H, Collomb H. Sexual behavior in psychomotor epileptics. Ann Med Psychol (Paris) 1954;112(2 Pt 5):657–96.
29. Blumer D, Walker AE. Sexual behavior in temporal lobe epilepsy. A study of the effects of temporal lobectomy on sexual behavior. Arch Neurol 1967;16:37–43.
30. Blumer D. Hypersexual episodes in temporal lobe epilepsy. Am J Psychiatry 1970;126:1099–106.
31. Walker AE. The libidinous temporal lobe. Schweiz Arch Neurol Neurochir Psychiatr 1972;111:473–84.
32. Shukla GD, Srivastava ON, Katiyar BC. Sexual disturbances in temporal lobe epilepsy: a controlled study. Br J Psychiatry 1979;134:288–92.
33. Demerdash A, Shaalan M, Midani A, Kamel F, Bahri M. Sexual behavior of a sample of females with epilepsy. Epilepsia 1991;32:82–5.
34. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol 1986;43:347–50.
35. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341–6.
36. Baird AD, Wilson SJ, Bladin PF, Saling MM, Reutens DC. Hypersexuality after temporal lobe resection. Epilepsy Behav 2002; 3:173–81.
37. Lilly R, Cummings JL, Benson DF, Frankel M. The human Kluver-Bucy syndrome. Neurology 1983;33:1141–5.
38. Miller BL, Cummings JL, McIntyre H, Ebers G, Grode M. Hypersexuality or altered sexual preference following brain injury. J Neurol Neurosurg Psychiatry 1986;49:867–73.
39. Leutmezer F, Serles W, Bacher J, et al. Genital automatisms in complex partial seizures. Neurology 1999;52:1188–91.
40. Anson JA, Kuhlman DT. Postictal Kluver-Bucy syndrome after temporal lobectomy. J Neurol Neurosurg Psychiatry 1993;56:311–3.
41. Janszky J, Szucs A, Halasz P, et al. Orgasmic aura originates from the right hemisphere. Neurology 2002;58:302–4.
42. Mitchell W, Falconer MA, Hill D. Epilepsy with fetishism relieved by temporal lobectomy. Lancet 1954;267:626–30.
43. Gorman DG, Cummings JL. Hypersexuality following septal injury. Arch Neurol 1992;49:308–10.
44. Meyers R. Three cases of myoclonus alleviated by bilateral ansotomy, with a note on postoperative alibido and impotence. J Neurosurg 1962;19:71–81.
45. Mendez MF, O'Connor SM, Lim GT. Hypersexuality after right pallidotomy for Parkinson's disease. J Neuropsychiatry Clin Neurosci 2004;16:37–40.
46. Frith CD. The social brain? Philos Trans R Soc Lond B Biol Sci 2007;362:671–8.
47. Fowler CJ, Griffiths DJ. A decade of functional brain imaging applied to bladder control. Neurourol Urodyn 2010;29:49–55.
48. Ueki Y. Micturitional disturbance in patients with brain tumour. Sogo Rinsho 1960;9:1361–70.
49. Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J Neurol Sci 1965;2:307–27.
50. Fisher CM. Hydrocephalus as a cause of disturbances of gait in the elderly. Neurology 1982;32:1358–63.
51. Kell CA, von Kriegstein K, Rosler A, Kleinschmidt A, Laufs H. The sensory cortical representation of the human penis: revisiting somatotopy in the male homunculus. J Neurosci 2005;25:5984–7.
52. Erickson TC. Erotomania (nymphomania) as an expression of cortical epileptiform discharge. Arch Neurol Psych 1945;53:226–31.
53. Terzian H, Ore GD. Syndrome of Kluver and Bucy; reproduced in man by bilateral removal of the temporal lobes. Neurology 1955;5:373–80.
54. Powers JM, Schaumburg HH, Gaffney CL. Kluver-Bucy syndrome caused by adreno-leukodystrophy. Neurology 1980;30:1231–2.
55. Mendez MF, Chow T, Ringman J, Twitchell G, Hinkin CH. Pedophilia and temporal lobe disturbances. J Neuropsychiatry Clin Neurosci 2000;12:71–6.
56. Edwards-Lee T, Miller BL, Benson DF, et al. The temporal variant of frontotemporal dementia. Brain 1997;120(Pt 6):1027–40.
57. Baird AD, Wilson SJ, Bladin PF, Saling MM, Reutens DC. Sexual outcome after epilepsy surgery. Epilepsy Behav 2003;4:268–78.
58. Baird AD, Wilson SJ, Bladin PF, Saling MM, Reutens DC. The amygdala and sexual drive: insights from temporal lobe epilepsy surgery. Ann Neurol 2004;55:87–96.
59. Toone BK, Wheeler M, Nanjee M, Fenwick P, Grant R. Sex hormones, sexual activity and plasma anticonvulsant levels in male epileptics. J Neurol Neurosurg Psychiatry 1983;46:824–6.
60. Rattya J, Turkka J, Pakarinen AJ, et al. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001;56:31–6.
61. Ranson SW. Some functions of the hypothalamus: Harvey lecture, December 17, 1936. Bull N Y Acad Med 1937;13:241–71.
62. Stuart DG, Portner RW, Adey WR, Kamikawa Y. Hypothalamic unit activity: visceral and somatic influences. Electroencephalogr Clin Neurophysiol 1964;16:237–41.
63. Enoch DM, Kerr FW. Hypothalamic vasopressor and vesicopressor pathways. II. Anatomic study of their course and connections. Arch Neurol 1967;16:307–20.
64. Blok B, Willemsen T, Holstege G. A PET study of brain control of micturition in humans. Brain 1997;120:111–21.
65. Spillane JD. Five boxers. Br Med J 1962;2:1205–10.
66. Krishna AY, Blevins LS, Jr. Case report: reversible gastroparesis in patients with hypopituitary disease. Am J Med Sci 1996;312:43–5.
67. MacLean PD, Ploog DW. Cerebral representation of penile erection. J Neurophysiol 1962;25:29–55.
68. Heath RG. Pleasure and brain activity in man. Deep and surface electroencephalograms during orgasm. J Nerv Ment Dis 1972;154:3–18.
69. Poeck K, Pilleri G. Release of hypersexual behaviour due to lesion in the limbic system. Acta Neurol Scand 1965;41:233–44.
70. Frohman EM, Frohman TC, Moreault AM. Acquired sexual paraphilia in patients with multiple sclerosis. Arch Neurol 2002;59:1006–10.
71. Crompton MR. Hypothalamic lesions following closed head injury. Brain 1971;94:165–72.
72. Rees PM, Fowler CJ, Maas CP. Sexual function in men and women with neurological disorders. Lancet 2007;369:512–25.
73. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265–73.
74. Muller D, Roeder F, Orthner H. Further results of stereotaxis in the human hypothalamus in sexual deviations. First use of this operation in addiction to drugs. Neurochirurgia (Stuttg) 1973;16:113–26.
75. Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002;17:1371–4.
76. Roane DM, Yu M, Feinberg TE, Rogers JD. Hypersexuality after pallidal surgery in Parkinson disease. Neuropsychiatry Neuropsychol Behav Neurol 2002;15:247–51.
77. Giovannoni G, O'sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423–8.
78. DasGupta R, Kavia RB, Fowler CJ. Cerebral mechanisms and voiding function. BJU Int 2007;99:731–4.
79. Bradley WE, Teague CT. Cerebellar regulation of the micturition reflex. J Urol 1969;101:396–9.
80. Rasheed BM, Manchanda SK, Anand BK. Effects of the stimulation of paleocerebellum on certain vegetative functions in the cat. Brain Res 1970;20:293–308.
81. Martner J. Influences on the defaecation and micturition reflexes by the cerebellar fastigial nucleus. Acta Physiol Scan 1975;94:95–104.
82. Huang TF, Yang CP, Yang SL. The role of the fastigial nucleus in bladder control. Exp Neurol 1979;66:674–81.
83. Nishizawa O, Ebina K, Sugaya K, et al. Effect of cerebellectomy on reflex micturition in the decerebrate dog as determined by urodynamic evaluation. Urol Int 1989;44:152–6.
84. Dietrichs E, Haines DE. Possible pathways for cerebellar modulation of autonomic responses: micturition. Scand J Urol Nephrol Suppl 2002;210:16–20.
85. Zhu JN, Yung WH, Kwok-Chong Chow B, Chan YS, Wang JJ. The cerebellar-hypothalamic circuits: potential pathways underlying cerebellar involvement in somatic-visceral integration. Brain Res Rev 2006;52:93–106.
86. Nardulli R, Monitillo V, Losavio E, et al. Urodynamic evaluation of 12 ataxic subjects: neurophysiopathologic considerations. Funct Neurol 1992;7:223–5.
87. Leach G, Farsaii A, Kark P, Raz S. Urodynamic manifestations of cerebellar ataxia. J Urol 1982;128:348–50.
88. Charil A, Zijdenbos AP, Taylor J, et al. Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets. Neuroimage 2003;19:532–44.
89. Sakakibara R, Uchida Y, Uchiyama T, Yamanishi T, Hattori T. Reduced cerebellar vermis activation during urinary storage and micturition in multiple system atrophy: 99mTc-labelled ECD SPECT study. Eur J Neurol 2004;11:705–8.
90. Pollack IF, Polinko P, Albright AL, Towbin R, Fitz C. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery 1995;37:885–93.
91. Sakakibara R, Hattori T, Fukutake T, et al. Micturitional disturbance in herpetic brainstem encephalitis; contribution of the pontine micturition center (PMC). J Neurol Neurosurg Psychiatry 1998;64:269–72.
92. Nagano M, Ishimizu Y, Saitoh S, Okada H, Fukuda H. The defecation reflex in rats: fundamental properties and the reflex center. Auton Neurosci 2004;111:48–56.
93. Valentino RJ, Miselis RR, Pavcovich LA. Pontine regulation of pelvic viscera: pharmacological target for pelvic visceral dysfunctions. Trends Pharmacol Sci 1999;20:253–60.
94. Khan Z, Hertanu J, Yang W, Melman A, Leiter E. Predictive correlation of urodynamic dysfunction and brain injury after cerebrovascular accident. J Urol 1981;126:86–8.
95. Khan Z, Starer P, Yang WC, Bhola A. Analysis of voiding disorders in patients with cerebrovascular accidents. Urology 1990;35:265–70.
96. Wade DT, Hewer RL. Outlook after an acute stroke: urinary incontinence and loss of consciousness compared in 532 patients. Q J Med 1985;56:601–8.
97. Patel M, Coshall C, Lawrence E, Rudd AG, Wolfe CD. Recovery from poststroke urinary incontinence: associated factors and impact on outcome. J Am Geriatr Soc 2001;49:1229–33.
98. Robain G, Chennevelle JM, Petit F, Piera JB. Incidence of constipation after recent vascular hemiplegia: a prospective cohort of 152 patients. Rev Neurol (Paris) 2002;158(5 Pt 1):589–92.
99. Bracci F, Badiali D, Pezzotti P, et al. Chronic constipation in hemiplegic patients. World J Gastroenterol 2007;13:3967–72.
100. Otegbayo JA, Talabi OA, Akere A, et al. Gastrointestinal complications in stroke survivors. Trop Gastroenterol 2006;27:127–30.
101. Harari D, Coshall C, Rudd AG, Wolfe CD. New-onset fecal incontinence after stroke: prevalence, natural history, risk factors, and impact. Stroke 2003;34:144–50.
102. Shamliyan T, Wyman J, Bliss DZ, Kane RL, Wilt TJ. Prevention of urinary and fecal incontinence in adults. Evid Rep Technol Assess (Full Rep) 2007;161:1–379.
103. Brittain K, Perry S, Shaw C, et al. Isolated urinary, fecal, and double incontinence: prevalence and degree of soiling in stroke survivors. J Am Geriatr Soc 2006;54:1915–9.
104. Nakayama H, Jorgensen HS, Pedersen PM, Raaschou HO, Olsen TS. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. Stroke 1997;28:58–62.
105. Jeon SW, Yoo KH, Kim TH, Kim JI, Lee CH. Correlation of the erectile dysfunction with lesions of cerebrovascular accidents. J Sex Med 2009;6:251–6.
106. Tang B, Zhou GQ, Zhao WX, et al. Characteristics of erectile dysfunction in old males with lacunar infarction. Zhonghua Nan Ke Xue 2006;12:798–9, 802.
107. Giaquinto S, Buzzelli S, Di Francesco L, Nolfe G. Evaluation of sexual changes after stroke. J Clin Psychiatry 2003;64:302–7.
108. Korpelainen JT, Kauhanen ML, Kemola H, Malinen U, Myllyla VV. Sexual dysfunction in stroke patients. Acta Neurol Scand 1998;98:400–5.
109. Monga TN, Lawson JS, Inglis J. Sexual dysfunction in stroke patients. Arch Phys Med Rehabil 1986;67:19–22.
110. Mutarelli EG, Omuro AM, Adoni T. Hypersexuality following bilateral thalamic infarction: case report. Arq Neuropsiquiatr 2006;64:146–8.
111. Resnick NM. Urinary incontinence. Lancet 1995;346:94–9.
112. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population. Int J Urol 2008;15:778–88.
113. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007;22:1581–6.
114. Allan L, McKeith I, Ballard C, Kenny RA. The prevalence of autonomic symptoms in dementia and their association with physical activity, activities of daily living and quality of life. Dement Geriatr Cogn Disord 2006;22:230–7.
115. Stokes G. Psychological approaches to bowel care in older people with dementia. In: Potter J, Norton C, Cottenden A, eds. Bowel care in older people. London: Royal College of Physicians; 2002.
116. Sakakibara R, Ogata T, Uchiyama T, et al. How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatr Soc 2009;57:1515–7.
117. Zeiss AM, Davies HD, Wood M, Tinklenberg JR. The incidence and correlates of erectile problems in patients with Alzheimer's disease. Arch Sex Behav 1990;19:325–31.
118. Elliott ML, Biever LS. Head injury and sexual dysfunction. Brain Inj 1996;10:703–17.
119. Aloni R, Katz S. A review of the effect of traumatic brain injury on the human sexual response. Brain Inj 1999;13:269–80.
120. Bruckner FE, Randle AP. Return to work after severe head injuries. Rheumatol Phys Med 1972;11:344–8.
121. Sandel ME, Williams KS, Dellapietra L, Derogatis LR. Sexual functioning following traumatic brain injury. Brain Inj 1996;10:719–28.
122. Hibbard MR, Gordon WA, Flanagan S, Haddad L, Labinsky E. Sexual dysfunction after traumatic brain injury. NeuroRehabilitation 2000;15:107–20.
123. Kreuter M, Dahllof AG, Gudjonsson G, Sullivan M, Siosteen A. Sexual adjustment and its predictors after traumatic brain injury. Brain Inj 1998;12:349–68.
124. Rosenbaum M, Najenson T. Changes in life patterns and symptoms of low mood as reported by wives of severly brain-injured soldiers. J Consult Clin Psychol 1976;44:881–8.
125. Ghigo E, Masel B, Aimaretti G, et al. Consensus guidelines on screening for hypopituitarism following traumatic brain injury. Brain Inj 2005;19:711–24.
126. Moiyadi AV, Devi BI, Nair KP. Urinary disturbances following traumatic brain injury: clinical and urodynamic evaluation. NeuroRehabilitation 2007;22:93–8.
127. Wyndaele JJ. Micturition in comatose patients. J Urol 1986;135:1209–11.
128. Krimchansky BZ, Sazbon L, Heller L, Kosteff H, Luttwak Z. Bladder tone in patients in post-traumatic vegetative state. Brain Inj 1999;13:899–903.

References

1. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309–16.
2. Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001;92:76–85.
3. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456–62.
4. Ueki A, Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 2004;251(Suppl 7):18–23.
5. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121–34.
6. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003;110:517–36.
7. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007;33:599–614.
8. Hansen MB. Neurohumoral control of gastrointestinal motility. Physiol Res 2003;52:1–30.
9. Liu MT, Rayport S, Jiang Y, Murphy DL, Gershon MD. Expression and function of 5-HT3 receptors in the enteric neurons of mice lacking the serotonin transporter. Am J Physiol Gastrointest Liver Physiol 2002;283:G1398–411.
10. Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol Motil 2005;17:637–42.
11. Walker JK, Gainetdinov RR, Mangel AW, Caron MG, Shetzline MA. Mice lacking the dopamine transporter display altered regulation of distal colonic motility. Am J Physiol Gastrointest Liver Physiol 2000;279:G311–8.
12. Anlauf M, Schafer MK, Eiden L, Weihe E. Chemical coding of the human gastrointestinal nervous system: cholinergic, VIPergic, and catecholaminergic phenotypes. J Comp Neurol 2003;459:90–111.
13. Vaughan CJ, Aherne AM, Lane E, et al. Identification and regional distribution of the dopamine D(1A) receptor in the gastrointestinal tract. Am J Physiol Regul Integr Comp Physiol 2000;279:R599–609.
14. Haskel Y, Hanani M. Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanisms. Dig Dis Sci 1994;39:2364–7.
15. Banach T, Zurowski D, Gil K, et al. Peripheral mechanisms of intestinal dysmotility in rats with salsolinol induced experimental Parkinson's disease. J Physiol Pharmacol 2006;57:291–300.
16. Miyamoto-Kikuta S, Ezaki T, Komuro T. Distribution and morphological characteristics of the interstitial cells of Cajal in the ileocaecal junction of the guinea-pig. Cell Tissue Res 2009;338:29–35.
17. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67–72.
18. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology 1984;87:848–56.
19. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997;38(Suppl 2):2–7.
20. Wang SJ, Fuh JL, Shan DE, et al. Sympathetic skin response and R-R interval variation in Parkinson's disease. Mov Disord 1993;8:151–7.
21. Gai WP, Blessing WW, Blumbergs PC. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. Brain 1995;118(Pt 6):1447–59.
22. Gravante G, Sabatino M, Sorbera F, Ferraro G, La Grutta V. Effects of substantia nigra stimulation on electrical and mechanical activities of the duodeno-jejunal loop, in the cat. Arch Int Physiol Biochim 1985;93:93–100.
23. Jing H, Lin KW, Mei MH. Participation of dopamine on the muscarinergic inhibitory effect of substance P on gastric myoelectric activity and motility. Sheng Li Xue Bao 1995;47:245–52.
24. Bueno L, Gue M, Fabre C, Junien JL. Involvement of central dopamine and D1 receptors in stress-induced colonic motor alterations in rats. Brain Res Bull 1992;29:135–40.
25. Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991;6:151–6.
26. Singer C, Weiner W, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson's disease. European Neurology 1992;32:134–40.
27. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey. Parkinsonism Relat Disord 2002;8:277–84.
28. Robson KM, Kiely DK, Lembo T. Development of constipation in nursing home residents. Dis Colon Rectum 2000;43:940–3.
29. Jost WH. Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 1997;10:249–58.
30. Shimada J, Sakakibara R, Uchiyama T, et al. Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a chronically constipated parkinsonian patient. Eur J Neurol 2006;13:306–7.
31. Yokoyama T, Hasegawa I. Ileus in Parkinson's disease. Neurological Medicine 2007;66:6–11.
32. Rosenthal MJ, Marshall CE. Sigmoid volvulus in association with parkinsonism. Report of four cases. J Am Geriatr Soc 1987;35:683–4.
33. Jost WH, Schrank B. Defecatory disorders in de novo Parkinsonians – colonic transit and electromyogram of the external anal sphincter. Wien Klin Wochenschr 1998;110:535–7.
34. Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:268–72.
35. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 1997;12:946–51.
36. Libelius R, Johanson JF. Quantitative electromyography of the external anal sphincter in Parkinson's disease and multiple system atrophy. Muscle & Nerve 2000;23:1250–6.
37. Stocchi F, Badiali D, Vacca L, et al. Anorectal function in multiple system atrophy and Parkinson's disease. Mov Disord 2000;15:71–6.
38. Ito T, Sakakibara R, Uchiyama T, et al. Videomanometry of the pelvic organs: a comparison of the normal lower urinary and gastrointestinal tracts. Int J Urol 2006;13:29–35.
39. Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 2000;164:1640–3.
40. Iscoe S. Control of abdominal muscles. Prog Neurobiol 1998;56:433–506.
41. Fontana GA, Pantaleo T, Lavorini F, Benvenuti F, Gangemi S. Defective motor control of coughing in Parkinson's disease. Am J Respir Crit Care Med 1998;158:458–64.
42. Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989;46:1061–4.
43. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 1993;33:490–3.
44. Astarloa R, Mena MA, Sanchez V, de la Vega L, de Yebenes JG. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992;15:375–80.
45. Ashraf W, Wszolek ZK, Pfeiffer RF, et al. Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. Mov Disord 1995;10:650–7.
46. Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1176–7.
47. Sakakibara R, Yamaguchi T, Uchiyama T, et al. Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjects. Mov Disord 2007;22:1672–3.
48. Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. 1997;12:952–7.
49. Shindler JS, Finnerty GT, Towlson K, et al. Domperidone and levodopa in Parkinson's disease. Br J Clin Pharmacol 1984;18:959–62.
50. Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995;10:81–4.
51. Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005;20:680–6.
52. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 2006;21:115–6.
53. Cadeddu F, Bentivoglio AR, Brandara F, et al. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment. Aliment Pharmacol Ther 2005;22:997–1003.
54. Chiarioni G, Heymen S, Whitehead WE. Biofeedback therapy for dyssynergic defecation. World J Gastroenterol 2006;12:7069–74.
55. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–8.
56. Staskin DS, Vardi Y, Siroky MA. Post-prostatectomy incontinence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol 1988;140:117–8.
57. Routh JC, Crimmins CR, Leibovich BC, Elliott DS. Impact of Parkinson's disease on continence after radical prostatectomy. Urology 2006;68:575–7.
58. Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and parkinson's disease – should transurethral resection of the prostate be avoided? J Urol 2009;181:2209–13.
59. Andersen JT, Bradley WE. Cystometric, sphincter and electromyelographic abnormalities in Parkinson's disease. J Urol 1976;116:75–8.
60. Berger Y, Blaivas JG, DeLaRocha ER, Salinas JM. Urodynamic findings in Parkinson's disease. J Urol 1987;138:836–8.
61. Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson's disease. J Urol 1983;129:80–3.
62. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 2000;68:429–33.
63. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916–23.
64. Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007;22:1623–9.
65. Sakakibara R, Shinotoh H, Uchiyama T, et al. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci 2001;187:55–9.
66. Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. Eur J Neurol 2005;12:842–50.
67. Yoshimura N, Sasa M, Yoshida O, Takaori S. Mediation of micturition reflex by central norepinephrine from the locus coeruleus in the cat. J Urol 1990;143:840–3.
68. Seki S, Igawa Y, Kaidoh K, et al. Role of dopamine D1 and D1 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 2001;20:105–13.
69. Yamamoto T, Sakakibara R, Nakazawa K, et al. Effects of electrical stimulation of the striatum on bladder activity in cats. Neurourol Urodyn 2009;28:549–54.
70. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737–45.
71. Finazzi-Agro E, Peppe A, D'Amico A, et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease. J Urol 2003;169:1388–91.
72. Sakakibara R, Nakazawa K, Uchiyama T, et al. Effects of subthalamic nucleus stimulation on the micturation reflex in cats. Neuroscience 2003;120:871–5.
73. Seif C, Herzog J, van der Horst C, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 2004;55:118–20.
74. Herzog J, Weiss PH, Assmus A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease. Brain 2006;129:3366–75.
75. Gerschlager W, Alesch F, Cunnington R, et al. Bilateral subthalamic nucleus stimulation improves frontal cortex function in Parkinson's disease. An electrophysiological study of the contingent negative variation. Brain 1999;122(Pt 12):2365–73.
76. Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn 2004;23:689–96.
77. Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 2003;18:573–8.
78. Christmas T, Kempster P, Chapple C, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2:1451–3.
79. Fitzmaurice H, Fowler CJ, Rickards D, et al. Micturition disturbance in Parkinson's disease. Br J Urol 1985;57:652–6.
80. Aranda B, Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn 1993;12:203–9.
81. Brusa L, Petta F, Pisani A, et al. Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease. J Urol 2006;175:202–6.
82. Yoshimura N, Mizuta E, Yoshida O, Kuno S. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 1998;286:228–33.
83. Kuno S, Mizuta E, Yamasaki S, Araki I. Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients. Parkinsonism Relat Disord 2004;10:181–7.
84. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–72.
85. Sakakibara R, Ito T, Uchiyama T, et al. Lower urinary tract function in dementia of Lewy body type. J Neurol Neurosurg Psychiatry 2005;76:729–32.
86. Kay GG, Abou-Donia MB, Messer WS, Jr., et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005;53:2195–201.
87. Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005;27:127–38.
88. Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry 2010;81:160–5.
89. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 1990;510:104–7.
90. Ito T, Sakakibara R, Nakazawa K, et al. Effects of electrical stimulation of the raphe area on the micturition reflex in cats. Neuroscience 2006;142:1273–80.
91. Andersson KE. Treatment of overactive bladder: other drug mechanisms. Urology 2000;55:51–7.
92. Schurch B, Hauri D, Rodic B, et al. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996;155:1023–9.
93. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452–7.
94. Giannantoni A, Rossi A, Mearini E, et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009;182:1453–7.
95. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001;53:417–50.
96. Montorsi F, Perani D, Anchisi D, et al. Apomorphine-induced brain modulation during sexual stimulation: a new look at central phenomena related to erectile dysfunction. Int J Impot Res 2003;15:203–9.
97. Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann Neurol 1978;3:129–33.
98. Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J Neurol 1991;238:19–22.
99. Ready RE, Friedman J, Grace J, Fernandez H. Testosterone deficiency and apathy in Parkinson's disease: a pilot study. J Neurol Neurosurg Psychiatry 2004;75:1323–6.
100. Brown RG, Jahanshahi M, Quinn N, Marsden CD. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry 1990;53:480–6.
101. Bronner G, Royter V, Korczyn AD, Giladi N. Sexual dysfunction in Parkinson's disease. J Sex Marital Ther 2004;30:95–105.
102. Feldman H, Goldstein I, Hatzichristou D, Krane R, McKinlay J. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61.
103. Lipe H, Longstreth WT, Jr., Bird TD, Linde M. Sexual function in married men with Parkinson's disease compared to married men with arthritis. Neurology 1990;40:1347–9.
104. Chandler BJ, Brown S. Sex and relationship dysfunction in neurological disability. J Neurol Neurosurg Psychiatry 1998;65:877–80.
105. Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S. Erectile dysfunction in Parkinson's disease. Urology 2006;67:447–51.
106. Jacobs H, Vieregge A, Vieregge P. Sexuality in young patients with Parkinson's disease: a population based comparison with healthy controls. J Neurol Neurosurg Psychiatry 2000;69:550–2.
107. Welsh M, Hung L, Waters CH. Sexuality in women with Parkinson's disease. Mov Disord 1997;12:923–7.
108. Wermuth L, Stenager E. Sexual problems in young patients with Parkinson's disease. Acta Neurol Scand 1995;91:453–5.
109. Heaton J. Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neuroscience and Behavioral Reviews 2000;24:561–9.
110. Eardley I, Wright P, MacDonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93:1271–5.
111. O'Sullivan J, Hughes A. Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 1998;13:536–9.
112. Safarinejad MR. Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. Int J Impot Res 2006;18:550–8.
113. Pohanka M, Kanovsky P, Bares M, Pulkrabek J, Rektor I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Parkinsonism Relat Disord 2005;11:509–12.
114. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000;15:305–8.
115. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371–4.
116. Castelli L, Perozzo P, Genesia ML, et al. Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2004;75:1260–4.
117. Ballivet J, Marin A, Gisselmann A. Aspects of hypersexuality observed in parkinsonian patients treated by L-dopa. Ann Med Psychol (Paris) 1973;2:515–22.
118. Gisselmann A. Hypersexuality and L dopa. Nouv Presse Med 1973;2:1616.
119. Brown E, Brown GM, Kofman O, Quarrington B. Sexual function and affect in parkinsonian men treated with L-dopa. Am J Psychiatry 1978;135:1552.
120. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381–6.
121. Kanovsky P, Bares M, Pohanka M, Rektor I. Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease. J Neurol 2002;249:112–4.
122. Shapiro MA, Chang YL, Munson SK, Okun MS, Fernandez HH. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord 2006;12:392–5.
123. Uitti RJ, Tanner CM, Rajput AH, et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 1989;12:375–83.
124. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67:1254–7.
125. Fenu S, Wardas J, Morelli M. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behav Pharmacol 2009;20:363–79.
126. O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23:157–70.
127. Bach JP, Oertel WH, Dodel R, Jessen F. Treatment of hypersexuality in Parkinson's disease with carbamazepine – a case report. Mov Disord 2009;24:1241–2.
128. Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002;17:1371–4.
129. Roane DM, Yu M, Feinberg TE, Rogers JD. Hypersexuality after pallidal surgery in Parkinson disease. Neuropsychiatry Neuropsychol Behav Neurol 2002;15:247–51.

References

1. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670–6.
2. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94:79–100.
3. Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004;127(Pt 12):2657–71.
4. Quinn N. Parkinsonism – recognition and differential diagnosis. BMJ 1995;310:447–52.
5. Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 1997;80:100–4.
6. Yamamoto T, Sakakibara R, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov Disord 2009;24:972–8.
7. Kirby R, Fowler C, Gosling J, Bannister R. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry 1986;49:554–562.
8. Salinas JM, Berger Y, De La Rocha RE, Blaivas JG. Urological evaluation in the Shy Drager syndrome. J Urol 1986;135:741–3.
9. Stocchi F, Carbone A, Inghilleri M, et al. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997;62:507–11.
10. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001;71:600–6.
11. Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 2007;27:484–93.
12. Benarroch EE, Schmeichel AM, Low PA, Parisi JE. Involvement of medullary serotonergic groups in multiple system atrophy. Ann Neurol 2004;55:418–22.
13. Sakakibara R, Uchida Y, Uchiyama T, Yamanishi T, Hattori T. Reduced cerebellar vermis activation during urinary storage and micturition in multiple system atrophy: 99mTc-labelled ECD SPECT study. Eur J Neurol 2004;11:705–8.
14. Ito T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 2006;21:816–23.
15. Hahn K, Ebersbach G. Sonographic assessment of urinary retention in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 2005;20:1499–502.
16. Yamamoto T, Sakakibara R, Uchiyama T, et al. Neurological diseases that cause detrusor hyperactivity with impaired contractile function. Neurourol Urodyn 2006;25:356–60.
17. Mannen T, Iwata M, Toyokura Y, Nagashima K. The Onuf's nucleus and the external anal sphincter muscle in ALS and Shy-Drager syndrome. Acta Neuropathol 1982;58:255–60.
18. Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 2008;115:443–60.
19. Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997;20:1396–403.
20. Tison F, Arne P, Sourgen C, Chrysostome V, Yeklef F. The value of external anal sphincter electromyography for the diagnsosis of multiple system atrophy. Mov Disord 2000;15:1148–57.
21. Giladi N, Simon ES, Korczyn AD, et al. Anal sphincter EMG does not distinguish between multiple system atrophy and parkinson's disease. Muscle Nerve 2000;23:731–4.
22. Podnar S, Fowler CJ. Sphincter electromyography in diagnosis of multiple system atrophy: technical issues. Muscle Nerve 2004;29:151–6.
23. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Sphincter EMG as a diagnostic tool in autonomic disorders. Clin Auton Res 2009;19:20–31.
24. Pramstaller PP, Wenning GK, Smith SJ, et al. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:618–21.
25. Paviour DC, Williams D, Fowler CJ, Quinn NP, Lees AJ. Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis. Mov Disord 2005;20:1425–30.
26. Mashidori T, Yamanishi T, Yoshida K, et al. Continuous urinary incontinence presenting as the initial symptoms demonstrating acontractile detrusor and intrinsic sphincter deficiency in multiple system atrophy. Int J Urol 2007;14:972–4.
27. Lapides J, Friend CR, Ajemian EP, Reus WF . A new method for diagnosing the neurogenic bladder. Med Bull (Ann Arbor) 1962;28:166–80.
28. Sakakibara R, Hattori T, Uchiyama T, et al. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? J Neurol Neurosurg Psychiatry 2000;68:65–9.
29. Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 1994;151:1336–41.
30. Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999;67:620–3.
31. Kirchhof K, Apostolidis AN, Mathias CJ, Fowler CJ. Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study. Int J Impot Res 2003;15:293–8.
32. Papatsoris AG, Papapetropoulos S, Singer C, Deliveliotis C. Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn 2008;27:22–7.
33. Papapetropoulos S, Tuchman A, Laufer D, et al. Causes of death in multiple system atrophy. J Neurol Neurosurg Psychiatry 2007;78:327–9.
34. Sakakibara R, Hattori T, Uchiyama T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 2000;79:191–5.
35. Yamamoto T, Sakakibara R, Yamanaka Y, et al. Pyridostigmine in autonomic failure: can we treat postural hypotension and bladder dysfunction with one drug? Clin Auton Res 2006;16:296–8.
36. Ozawa T, Tanaka H, Nakano R, et al. Nocturnal decrease in vasopressin secretion into plasma in patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1999;67:542–5.
37. Sakakibara R, Matsuda S, Uchiyama T, et al. The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res 2003;13:106–8.
38. Benarroch EE, Schmeichel AM, Sandroni P, Low PA, Parisi JE. Differential involvement of hypothalamic vasopressin neurons in multiple system atrophy. Brain 2006;129(Pt 10):2688–96.
39. Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed) 1986;293:353–4.
40. Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time, sphincter EMG, and rectoanal videomanometry in multiple system atrophy. Mov Disord 2004;19:924–9.
41. Valentino RJ, Miselis RR, Pavcovich LA. Pontine regulation of pelvic viscera: pharmacological target for pelvic visceral dysfunctions. Trends Pharmacol Sci 1999;20:253–60.
42. Stocchi F, Badiali D, Vacca L, et al. Anorectal function in multiple system atrophy and Parkinson's disease. Mov Disord 2000;15:71–6.
43. Ashraf W, Wszolek ZK, Pfeiffer RF, et al. Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. Mov Disord 1995;10:650–7.
44. Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1176–7.
45. Sakakibara R, Yamaguchi T, Uchiyama T, et al. Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjects. Mov Disord 2007;22:1672–3.
46. Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005;20:680–6.
47. Sakakibara R, Odaka T, Lui Z, et al. Dietary herb extract dai-kenchu-to ameliorates constipation in parkinsonian patients (Parkinson's disease and multiple system atrophy). Mov Disord 2005;20:261–2.
48. Oertel WH, Wachter T, Quinn NP, Ulm G, Brandstadter D. Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type. Mov Disord 2003;18:430–2.
49. Dominguez JM, Hull EM. Dopamine, the medial preoptic area, and male sexual behavior. Physiol Behav 2005;86:356–68.
50. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371–4.
51. Winkler AS, Landau S, Chaudhuri KR. Serum prolactin levels in Parkinson's disease and multiple system atrophy. Clin Auton Res 2002;12:393–8.
52. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381–6.

References

1. World Health Organization, Multiple Sclerosis International Federation. Atlas: multiple sclerosis resources in the world. Geneva: World Health Organization; 2008.
2. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182–91.
3. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281–300.
4. Compston A, Confavreux C, Lassmann H, et al., eds. McAlpine's multiple sclerosis. London: Churchill Livingstone; 2006.
5. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128(Pt 11):2705–12.
6. Furby J, Hayton T, Anderson V, et al. Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler 2008;14:1068–75.
7. Bradl M, Lassmann H. Progressive multiple sclerosis. Semin Immunopathol 2009;31:455–65.
8. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52.
9. Kalita J, Shah S, Kapoor R, Misra UK. Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations. J Neurol Neurosurg Psychiatry 2002;73:154–9.
10. Awad SA, Gajewski JB, Sogbein SK, Murray TJ, Field CA. Relationship between neurological and urological status in patients with multiple sclerosis. J Urol 1984;132:499–502.
11. Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993;56:245–50.
12. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:470–7.
13. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430–8.
14. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126(Pt 4):770–82.
15. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology 2007;68:1971–8.
16. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 2004;97:671–6.
17. Giannantoni A, Scivoletto G, Di Stasi SM, et al. Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehabil 1999;80(4):437–41.
18. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007;13:915–28.
19. Koldewijn E, Hommes O, Lemmens W, Debruyne F, van Kerrebroeck P. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 1995;154:169–73.
20. Porru D, Campus G, Garau A, et al. Urinary tract dysfunction in multiple sclerosis: is there a relation with disease-related parameters? Spinal Cord 1997;35:33–6.
21. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs 2002;11:560–5.
22. McClurg D, Ashe RG, Marshall K, Lowe-Strong AS. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 2006;25:337–48.
23. Vahtera T, Haaranen M, Viramo-Koskela AL, Ruutiainen J. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehabil 1997;11:211–9.
24. Fowlis GA, Waters J, Williams G. The cost effectiveness of combined rapid tests (Multistix) in screening for urinary tract infections. J R Soc Med 1994;87:681–2.
25. Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology 2001;20:138–43.
26. Bemelmans BL, Hommes OR, Van Kerrebroeck PE, et al. Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. J Urol 1991;145:1219–24.
27. Sirls LT, Zimmern PE, Leach GE. Role of limited evaluation and aggressive medical management in multiple sclerosis: a review of 113 patients. J Urol 1994;151:946–50.
28. Kasabian N, Krause I, Brown W, Khan Z, Nagler H. Fate of the upper urinary tract in multiple sclerosis. Neurourol Urodyn 1995;14:81–5.
29. Gallien P, Robineau S, Nicolas B, et al. Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases. Arch Phys Med Rehabil 1998;79:255–7.
30. Vahter L, Zopp I, Kreegipuu M, et al. Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult Scler 2009;15:379–84.
31. O'Riordan JI, Doherty C, Javed M, et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol 1995;153:1114–6.
32. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98.
33. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 2003;17:42–7.
34. Abrams P, Agarwal M, Drake M, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int 2008;101:989–94.
35. Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986;135:966–8.
36. Ethans KD, Nance PW, Bard RJ, Casey AR, Schryvers OI. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004;27:214–8.
37. Amend B, Hennenlotter J, Schafer T, et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53:1021–8.
38. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50:317–26.
39. Bosma R, Wynia K, Havlikova E, De Keyser J, Middel B. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005;112:1–5.
40. Reynard JM, Cannon A, Yang Q, Abrams P. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 1998;81:215–8.
41. Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004;10:425–33.
42. Freeman RM, Adekanmi O, Waterfield MR, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17:636–41.
43. Kavia R, De Ridder D, Constantinescu S, Fowler C. Randomised controlled trial of Sativex to treat detrusor over activity in multiple sclerosis. Multiple Sclerosis 2010;submitted.
44. de Sèze M, Wiart L, Joseph PA, et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998;17:513–23.
45. Kim JH, Rivas DA, Shenot PJ, et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 2003;26:358–63.
46. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196–200.
47. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007;41:335–40.
48. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452–7.
49. Khan S, Kessler TM, Panicker J, et al. Sustained and significant quality of life improvement after intra-detrusor botulinum toxin type A injections for neurogenic detrusor overactivity secondary to multiple sclerosis. Br J Urol [Presentation] 2009;103:37.
50. Lekka E, Lee LK. Successful treatment with intradetrusor botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol 2006;50:806–9.
51. Game X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008;53:613–8.
52. Wallace PA, Lane FL, Noblett KL . Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 2007;197:96.e1–5.
53. Cappellano F, Bertapelle P, Spinelli M, et al. Quality of life assessment in patients who undergo sacral neuromodulation implantation for urge incontinence: an additional tool for evaluating outcome. J Urol 2001;166:2277–80.
54. Ruffion A, de Sèze M, Denys P, Perrouin-Verbe B, Chartier-Kastler E. Groupe d'Etudes de Neuro-Urologie de Langue Francaise (GENULF) guidelines for the management of spinal cord injury and spina bifida patients. Prog Urol 2007;17:631–3.
55. Stohrer M, Castro-Diaz D, Chartier-Kastler E, et al. Guidelines on neurogenic lower urinary tract dysfunction. Prog Urol 2007;17:687–99.
56. Hess MJ, Hess PE, Sullivan MR, Nee M, Yalla SV. Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord 2008;46:622–6.
57. Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125(Pt 5):952–60.
58. De Ridder D, van Poppel H, Demonty L, et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol 1998;159:1881–4.
59. Bonniaud V, Bryant D, Parratte B, Guyatt G. Development and validation of the short form of a urinary quality of life questionnaire: SF-Qualiveen. J Urol 2008;180:2592–8.
60. Hinds J, Wald A. Colonic and anorectal dysfunction associated with multiple sclerosis. Am J Gastroenterol 1989;84:587–95.
61. Hinds J, Eidelman B, Wald A. Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology 1990;98:1538–42.
62. Chia Y-W, Fowler C, Kamm M, et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol 1995;242:105–8.
63. Nordenbo A, Andersen J, Andersen J. Disturbances of ano-rectal function in multiple sclerosis. J Neurol 1996;243:445–51.
64. Bakke A, Myhr K, Gronning M, Nyland H. Bladder, bowel and sexual dysfunction in patients with multiple sclerosis – a cohort study. Scand J Urol Nephrol 1996;179(Suppl):61–6.
65. Munteis E, Andreu M, Tellez MJ, et al. Anorectal dysfunction in multiple sclerosis. Mult Scler 2006;12:215–8.
66. Wiesel PH, Norton C, Glickman S, Kamm MA. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol 2001;13:441–8.
67. National Institute for Clinical Excellence. Management of multiple sclerosis in primary and secondary care. London: NICE, 2003.
68. Preziosi G, Emmanuel A. Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol 2009;3:417–23.
69. Gore RM, Mintzer RA, Calenoff L. Gastrointestinal complications of spinal cord injury. Spine (Phila Pa 1976) 1981;6:538–44.
70. Glick ME, Meshkinpour H, Haldeman S, et al. Colonic dysfunction in patients with thoracic spinal cord injury. Gastroenterology 1984;86:287–94.
71. Aaronson MJ, Freed MM, Burakoff R. Colonic myoelectric activity in persons with spinal cord injury. Dig Dis Sci 1985;30:295–300.
72. Sun WM, Read NW, Donnelly TC. Anorectal function in incontinent patients with cerebrospinal disease. Gastroenterology 1990;99:1372–9.
73. Chia Y, Gill K, Jameson J, et al. Paradoxical puborectalis contraction is a feature of constipation in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:31–5.
74. Weber J, Grise P, Roquebert M, et al. Radiopaque markers transit and anorectal manometry in 16 patients with multiple sclerosis and urinary bladder dysfunction. Dis Colon Rectum 1987;30:95–100.
75. Waldron D, Horgan P, Patel F, Maguire R, Given H. Multiple sclerosis assessment of colonic and anorectal function in the presence of faecal incontinence. Int J Colorectal Dis 1993;8:220–4.
76. Preziosi G, Emmanuel A. Evidence of reduced rectal compliance in constipated patients with multiple sclerosis. In: Emmanuel A, ed. Association of Coloproctology of Great Britain and Ireland, Harrogate8–11/06/2009(Poster).
77. Nicoletti R, Mina A, Balzaretti G, Tessera G, Ghezzi A. Intestinal transit studied with radiopaque markers in patients with multiple sclerosis. Radiol Med 1992;83:428–30.
78. Glick E, Meshkinpour H, Haldeman S, Bhatia N, Bradley W. Colonic dysfunction in multiple sclerosis. Gastroenterology 1982;83:1002–7.
79. Haldeman S, Glick M, Bhatia NN, Bradley WE, Johnson B. Colonometry, cystometry, and evoked potentials in multiple sclerosis. Arch Neurol 1982;39:698–701.
80. Taylor MC, Bradley WE, Bhatia N, Glick M, Haldeman S. The conus demyelination syndrome in multiple sclerosis. Acta Neurol Scand 1984;69:80–9.
81. Jameson JS, Rogers J, Chia YW, et al. Pelvic floor function in multiple sclerosis. Gut 1994;35:388–90.
82. Swash M, Snooks SJ, Chalmers DHK. Parity as a factor in incontinence in multiple sclerosis. Arch Neurol 1987;44:504–8.
83. Mathers SE, Ingram DA, Swash M. Electrophysiology of motor pathways for sphincter control in multiple sclerosis. J Neurol Neurosurg Psychiatry 1990;53:955–60.
84. Snooks SJ, Swash M. Motor conduction velocity in the human spinal cord: slowed conduction in multiple sclerosis and radiation myelopathy. J Neurol Neurosurg Psychiatry 1985;48:1135–9.
85. Halligan S, Bartram CI, Park HJ, Kamm MA. Proctographic features of anismus. Radiology 1995;197:679–82.
86. Read NW, Timms JM, Barfield LJ, Donnelly TC, Bannister JJ. Impairment of defecation in young women with severe constipation. Gastroenterology 1986;90:53–60.
87. Speakman CT, Kamm MA. Abnormal visceral autonomic innervation in neurogenic faecal incontinence. Gut 1993;34:215–21.
88. Wiesel PH, Norton C, Roy AJ, et al. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;69:240–3.
89. Preziosi G, Thirupathy K, Boulos P, Emmanuel A. Successful biofeedback in patients with multiple sclerosis is related to disability and mood factors more than anorectal physiology variables. Gastroenterology 2009;136(5 Suppl 1):A380.
90. Munteis E, Andreu M, Martinez-Rodriguez J, et al. Manometric correlations of anorectal dysfunction and biofeedback outcome in patients with multiple sclerosis. Mult Scler 2008;14:237–42.
91. DasGupta R, Fowler CJ. Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol 2002;15:271–8.
92. Tepavcevic DK, Kostic J, Basuroski ID, et al. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler 2008;14:1131–6.
93. Foley FW, LaRocca NG, Sanders AS, Zemon V. Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. Mult Scler 2001;7:417–21.
94. Zorzon M, Zivadinov R, Monti Bragadin L, et al. Sexual dysfunction in multiple sclerosis: a 2 year follow-up study. J Neurol Sci 2001;187:1–5.
95. Zivadinov R, Zorzon M, Bosco A, et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 1999;5:428–31.
96. Betts CD, Jones SJ, Fowler CG, Fowler CJ. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain 1994;117(Pt 6):1303–10.
97. Valleroy ML, Kraft GH. Sexual dysfunction in multiple sclerosis. Arch Phys Med Rehab 1984;65:125–8.
98. Kirkeby HJ, Poulsen EU, Petersen T, Dorup J. Erectile dysfunction in multiple sclerosis. Neurol 1988;38:1366–71.
99. Staerman F, Guiraud P, Coeurdacier P, et al. Value of nocturnal penile tumescence and rigidity (NPTR) recording in impotent patients with multiple sclerosis. Int J Impot Res 1996;8:241–5.
100. Zivadinov R, Zorzon M, Bosco A, et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 1999;5:428–31.
101. Vas CJ. Sexual impotence and some autonomic disturbances in men with multiple sclerosis. Acta Neurol Scand 1969;45:166–82.
102. Witt MA, Grantmyre JE. Ejaculatory failure. World J Urol 1993;11:89–95.
103. Nortvedt MW, Riise T, Myhr KM, et al. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 2001;7(4):231–5.
104. Fraser C, Mahoney J, McGurl J. Correlates of sexual dysfunction in men and women with multiple sclerosis. J Neurosci Nurs 2008;40:312–7.
105. Tzortzis V, Skriapas K, Hadjigeorgiou G, et al. Sexual dysfunction in newly diagnosed multiple sclerosis women. Mult Scler 2008;14:561–3.
106. Gondim FA, Thomas FP. Episodic hyperlibidinism in multiple sclerosis. Mult Scler 2001;7:67–70.
107. Huws R, Shubsachs AP, Taylor PJ. Hypersexuality, fetishism and multiple sclerosis. Br J Psychiatry 1991;158:280–1.
108. Frohman EM, Frohman TC, Moreault AM. Acquired sexual paraphilia in patients with multiple sclerosis. Arch Neurol 2002;59:1006–10.
109. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urol 1997;49:822–30.
110. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.
111. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005;31:1–20.
112. Gruenwald I, Vardi Y, Gartman I, et al. Sexual dysfunction in females with multiple sclerosis: quantitative sensory testing. Mult Scler 2007;13:95–105.
113. Fowler CJ, Miller JR, Sharief MK, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005May;76(5):700–5.
114. Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol 2009;181:252–8.
115. Pavone C, Curto F, Anello G, et al. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol 2008;179(5 Suppl):S92–4.
116. Eardley I, Wright P, MacDonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93:1271–5.
117. Riley AJ. Yohimbine in the treatment of erectile disorder. Br J Clin Pract 1994;48:133–6.
118. Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. Pharmacol Ther 2001;91:215–43.
119. Soler JM, Previnaire JG, Plante P, Denys P, Chartier-Kastler E. Midodrine improves orgasm in spinal cord-injured men: the effects of autonomic stimulation. J Sex Med 2008;5:2935–41.
120. Dasgupta R, Wiseman OJ, Kanabar G, Fowler CJ, Mikol DD. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004;171:1189–93.
121. Saval A, Chiodo AE. Sexual dysfunction associated with intrathecal baclofen use: a report of two cases. J Spinal Cord Med 2008;31:103–5.
122. McGehee M, Hornyak JE, Lin C, Kelly BM. Baclofen-induced sexual dysfunction. Neurology 2006;67:1097–8.
123. Annon J. PLISSIT Therapy. In: Corsini R, ed. Handbook of innovative psychotherapies. New York: Wiley and Sons; 1981:626–39.
124. DaJusta DG, Wosnitzer MS, Barone JG. Persistent motor deficits predict long-term bladder dysfunction in children following acute transverse myelitis. J Urol 2008;180 (4 Suppl):1774–7.
125. Ito T, Sakakibara R, Uchiyama T, et al. Lower urinary tract dysfunction in central pontine myelinolysis: possible contribution of the pontine micturition centre. Eur J Neurol 2005;12:812–3.
126. Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance in acute disseminated encephalomyelitis (ADEM). J Auton Nerv Syst 1996;60:200–5.
127. Panicker J, Nagaraja D, Kovoor J, Nair K, Subbakrishna D. Lower urinary tract dysfunction in acute disseminated encephalomyelitis. Mult Scler 2009;15:1118–22.
128. Sakakibara R, Uchiyama T, Liu Z, et al. Meningitis-retention syndrome. An unrecognized clinical condition. J Neurol 2005;252:1495–9.
129. Sakakibara R, Hattori T, Fukutake T, et al. Micturitional disturbance in a patient with adrenomyeloneuropathy (AMN). Neurourol Urodyn 1998;17:207–12.
130. Alberca R, Iriarte LM, Rasero P, Villalobos F. Brachial diplegia in central pontine myelinolysis. J Neurol 1985;231:345–6.
131. Sakakibara R, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T. Urinary dysfunction in patients with systemic lupus erythematosis. Neurourol Urodyn 2003;22:593–6.
132. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Micturitional disturbance in subacute myelo-optico-neuropathy (SMON). Auton Neurosci 2001;87:282–5.
133. Graber JJ, Kister I, Geyer H, Khaund M, Herbert J. Neuromyelitis optica and concentric rings of Balo in the brainstem. Arch Neurol 2009;66:274–5.
134. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Micturitional disturbance in a patient with neurosarcoidosis. Neurourol Urodyn 2000;19:273–7.
135. Hiraga A, Sakakibara R, Mori M, et al. Urinary retention can be the sole initial manifestation of acute myelitis. J Neurol Sci 2006;251:110–2.
136. Pidcock FS, Krishnan C, Crawford TO, et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007;68:1474–80.
137. Pradhan S, Gupta RK, Kapoor R, Shashank S, Kathuria MK. Parainfectious conus myelitis. J Neurol Sci 1998;161:156–62.
138. Olson S, Rossato R, Guazzo E. Spinal schistosomiasis. J Clin Neurosci 2002;9:317–20.
139. Gomes CM, Trigo-Rocha F, Arap MA, et al. Schistosomal myelopathy: urologic manifestations and urodynamic findings. Urology 2002;59:195–200.
140. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Urinary dysfunction in Brown-Sequard syndrome. Neurourol Urodyn 2001;20:661–7.
141. Misra UK, Kalita J, Kumar G, Kapoor R. Bladder dysfunction in subacute combined degeneration: a clinical, MRI and urodynamic study. J Neurol 2008;255:1881–8.

References

1. Jackson AB, Dijkers M, Devivo MJ, Poczatek RB. A demographic profile of new traumatic spinal cord injuries: change and stability over 30 years. Arch Phys Med Rehabil 2004;85:1740–8.
2. Stover SL, Fine PR. The epidemiology and economics of spinal cord injury. Paraplegia 1987;25:225–8.
3. Ditunno JF, Jr., Young W, Donovan WH, Creasey G. The international standards booklet for neurological and functional classification of spinal cord injury. American Spinal Injury Association. Paraplegia 1994;32:70–80.
4. Alexander MS, Biering-Sorensen F, Bodner D, et al. International standards to document remaining autonomic function after spinal cord injury. Spinal Cord 2009;47:36–43.
5. Norris JP, Staskin DR. History, physical examination, and classification of neurogenic voiding dysfunction. Urol Clin North Am 1996;23:337–43.
6. Weld KJ, Graney MJ, Dmochowski RR. Clinical significance of detrusor sphincter dyssynergia type in patients with post-traumatic spinal cord injury. Urology 2000;56:565–8.
7. Patki P, Woodhouse J, Hamid R, Shah J, Craggs M. Lower urinary tract dysfunction in ambulatory patients with incomplete spinal cord injury. J Urol 2006;175:1784–7.
8. Moslavac S, Dzidic I, Kejla Z. Neurogenic detrusor overactivity: comparison between complete and incomplete spinal cord injury patients. Neurourol Urodyn 2008;27:504–6.
9. Krassioukov A, Warburton DE, Teasell R, Eng JJ. A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil 2009;90:682–95.
10. Curt A, Nitsche B, Rodic B, Schurch B, Dietz V. Assessment of autonomic dysreflexia in patients with spinal cord injury. J Neurol Neurosurg Psychiatry 1997;62:473–7.
11. Acute management of autonomic dysreflexia: adults with spinal cord injury presenting to health-care facilities. Consortium for spinal cord. J Spinal Cord Med 1997;20:284–308.
12. Chartier-Kastler E, Ruffion A. Démarche et bilan diagnostique en neuro-urologie. Prog Urol 2007;17:339–43.
13.Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med 2006;29:527–73.
14. Stohrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81–8.
15. Abrams P, Agarwal M, Drake M, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int 2008;101:989–94.
16. Alexander MS, Anderson KD, Biering-Sorensen F, et al. Outcome measures in spinal cord injury: recent assessments and recommendations for future directions. Spinal Cord 2009;47:582–91.
17. Thomassen SA, Johannesen IL, Erlandsen EJ, Abrahamsen J, Randers E. Serum cystatin C as a marker of the renal function in patients with spinal cord injury. Spinal Cord 2002;40:524–8.
18. Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol 2000;163:768–72.
19. Chang SM, Hou CL, Dong DQ, Zhang H. Urologic status of 74 spinal cord injury patients from the 1976 Tangshan earthquake, and managed for over 20 years using the Crede maneuver. Spinal Cord 2000;38:552–4.
20. Hall MK, Hackler RH, Zampieri TA, Zampieri JB. Renal calculi in spinal cord-injured patient: association with reflux, bladder stones, and foley catheter drainage. Urology 1989;34:126–8.
21. Ost MC, Lee BR. Urolithiasis in patients with spinal cord injuries: risk factors, management, and outcomes. Curr Opin Urol 2006;16:93–9.
22. Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology 2001;20:138–43.
23. Sekar P, Wallace DD, Waites KB, et al. Comparison of long-term renal function after spinal cord injury using different urinary management methods. Arch Phys Med Rehabil 1997;78:992–7.
24. Nicolle LE. Asymptomatic bacteriuria: review and discussion of the IDSA guidelines. Int J Antimicrob Agents 2006;28(Suppl 1):S42–8.
25. The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. January 27–29, 1992. J Am Paraplegia Soc 1992;15:194–204.
26. Kass EH. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians 1956;69:56–64.
27. Esclarin De Ruz A, Garcia Leoni E, Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol 2000;164:1285–9.
28. Whiteneck GG, Charlifue SW, Frankel HL, et al. Mortality, morbidity, and psychosocial outcomes of persons spinal cord injured more than 20 years ago. Paraplegia 1992;30:617–30.
29. Cardenas DD, Hoffman JM, Kirshblum S, McKinley W. Etiology and incidence of rehospitalization after traumatic spinal cord injury: a multicenter analysis. Arch Phys Med Rehabil 2004;85:1757–63.
30. Hess MJ, Hess PE, Sullivan MR, Nee M, Yalla SV. Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord 2008;46:622–6.
31. Salomon J, Denys P, Merle C, et al. Prevention of urinary tract infection in spinal cord-injured patients: safety and efficacy of a weekly oral cyclic antibiotic (WOCA) programme with a 2 year follow-up – an observational prospective study. J Antimicrob Chemother 2006;57:784–8.
32. McGuire EJ, Savastano JA. Urodynamics and management of the neuropathic bladder in spinal cord injury patients. J Am Paraplegia Soc 1985;8:28–32.
33. Pannek J. Transitional cell carcinoma in patients with spinal cord injury: a high risk malignancy? Urology 2002;59:240–4.
34. Kaufman JM, Fam B, Jacobs SC, et al. Bladder cancer and squamous metaplasia in spinal cord injury patients. J Urol 1977;118:967–71.
35. Navon JD, Soliman H, Khonsari F, Ahlering T. Screening cystoscopy and survival of spinal cord injured patients with squamous cell cancer of the bladder. J Urol 1997;157:2109–11.
36. Hamid R, Bycroft J, Arya M, Shah PJ. Screening cystoscopy and biopsy in patients with neuropathic bladder and chronic suprapubic indwelling catheters: is it valid? J Urol 2003;170(2 Pt 1):425–7.
37. Yang CC, Clowers DE. Screening cystoscopy in chronically catheterized spinal cord injury patients. Spinal Cord 1999;37:204–7.
38. Ruffion A, De Sèze M, Denys P, Perrouin-Verbe B, Chartier-Kastler E. Suivi des vessies neurologiques du blesse medullaire et du patient porteur d'une myelomeningocele. Revue de la litterature et recommandations pratiques de suivi. Pelv Perineol 2006;1:304–23.
39. Costa P, Perrouin-Verbe B, Colvez A, et al. Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen. Eur Urol 2001;39:107–13.
40. Zahariou A, Karagiannis G, Papaioannou P, Stathi K, Michail X. The use of desmopressin in the management of nocturnal enuresis in patients with spinal cord injury. Eura Medicophys 2007;43:333–8.
41. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000;342:665.
42. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008;53:275–87.
43. Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009;55:705–11.
44. Wyndaele JJ, Kovindha A, Madersbacher H, et al. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Paris: Editions 21; 2009.
45. Sievert KD, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol 2010;67:74–84.
46. Brindley GS. An implant to empty the bladder or close the urethra. J Neurol Neurosurg Psychiatry 1977;40:358–69.
47. Brindley GS. The actions of parasympathetic and sympathetic nerves in human micturition, erection and seminal emission, and their restoration in paraplegic patients by implanted electrical stimulators. Proc R Soc Lond 1988;235:111–20.
48. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:470–7.
49. Game X, Karsenty G, Chartier-Kastler E, Ruffion A. Traitement de l'hyperactivite detrusorienne neurologique: enterocystoplasties. Prog Urol 2007;17:584–96.
50. Timoney AG, Shaw PJ. Urological outcome in female patients with spinal cord injury: the effectiveness of intermittent catheterisation. Paraplegia 1990;28:556–63.
51. Glickman S, Kamm MA. Bowel dysfunction in spinal-cord-injury patients. Lancet 1996;347:1651–3.
52. Courtois F, Mathieu C, Charvier K. Sexual rehabilitation for men with spinal cord injury: preliminary report on a behavioral strategy. Sex Disabil 2001;19:153–7.
53. Lombardi G, Macchiarella A, Cecconi F, Del Popolo G. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. J Sex Med 2009;6:1248–58.
54. Soler JM, Previnaire JG, Denys P, Chartier-Kastler E. Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men. Spinal Cord 2007;45:169–73.
55. Deforge D, Blackmer J, Garritty C, et al. Male erectile dysfunction following spinal cord injury: a systematic review. Spinal Cord 2006;44:465–73.
56. Brindley GS. Electroejaculation: its technique, neurological implications and uses. J Neurol Neurosurg Psychiatry 1981;44:9–18.
57. Soler JM, Previnaire JG, Plante P, Denys P, Chartier-Kastler E. Midodrine improves orgasm in spinal cord-injured men: the effects of autonomic stimulation. J Sex Med 2008;5:2935–41.
58. Patki P, Hamid R, Shah J, Craggs M. Fertility following spinal cord injury: a systematic review. Spinal Cord 2007;45:187.
59. Sipski ML, Alexander CJ, Rosen R. Sexual arousal and orgasm in women: effects of spinal cord injury. Ann Neurol 2001;49:35–44.
60. Komisaruk BR, Whipple B. Functional MRI of the brain during orgasm in women. Annu Rev Sex Res 2005;16:62–86.
61. Sipski ML, Rosen RC, Alexander CJ, Hamer RM. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2000;55:812–5.
62. Forsythe E, Horsewell JE. Sexual rehabilitation of women with a spinal cord injury. Spinal Cord 2006;44:234–41.

References

1. Busby A, Abramsky L, Dolk H, Armstrong B. Preventing neural tube defects in Europe: population based study. BMJ 2005;330:574–5.
2. Mitchell LE, Adzick NS, Melchionne J, et al. Spina bifida. Lancet 2004;364:1885–95.
3. Pacheco SS, Braga C, Souza AI, Figueiroa JN. Effects of folic acid fortification on the prevalence of neural tube defects. Rev Saude Publica 2009;43:565–71.
4. Defoort EN, Kim PM, Winn LM. Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. Mol Pharmacol 2006;69:1304–10.
5. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991;338:131–7.
6. U.S. Food and Drug Administration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Reg 1996;61:8781–97.
7. Busby A, Abramsky L, Dolk H, et al. Preventing neural tube defects in Europe: a missed opportunity. Reprod Toxicol 2005;20:393–402.
8. Rothenberg SP, da Costa MP, Sequeira JM, et al. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004;350:134–42.
9. Bauer SB, Labib KB, Dieppa RA, Retik AB. Urodynamic evaluation of boy with myelodysplasia and incontinence. Urology 1977;10:354–62.
10. Thompson DN. Postnatal management and outcome for neural tube defects including spina bifida and encephalocoeles. Prenat Diagn 2009;29:412–9.
11. Sutton LN. Fetal surgery for neural tube defects. Best Pract Res Clin Obstet Gynaecol 2008;22:175–88.
12. Koh CJ, DeFilippo RL, Borer JG. Lower urinary tract function after fetal closure of myelomeningocele. J Urol Suppl 2003;169(Abstract 411).
13. Johnson MP, Sutton LN, Rintoul N, et al. Fetal myelomeningocele repair: short-term clinical outcomes. Am J Obstet Gynecol 2003;189:482–7.
14. Joseph DB. Bladder rehabilitation in children with spina bifida: state-of-the-“ART”. J Urol 2005;173:1850–1.
15. Moore C, Kogan BA, Parekh A. Impact of urinary incontinence on self-concept in children with spina bifida. J Urol 2004;171:1659–62.
16. Verhoef M, Lurvink M, Barf HA, et al. High prevalence of incontinence among young adults with spina bifida: description, prediction and problem perception. Spinal Cord 2005;43:331–40.
17. Hopps CV, Kropp KA. Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup. J Urol 2003;169:305–8.
18. Bauer SB. The management of the myelodysplastic child: a paradigm shift. BJU Int 2003;92(Suppl 1):23–8.
19. Kessler TM, Lackner J, Kiss G, Rehder P, Madersbacher H. Early proactive management improves upper urinary tract function and reduces the need for surgery in patients with myelomeningocele. Neurourol Urodyn 2006;25:758–62.
20. Dik P, Klijn AJ, van Gool JD, de Jong-de Vos van Steenwijk CC, de Jong TP . Early start to therapy preserves kidney function in spina bifida patients. Eur Urol 2006;49:908–13.
21. Kessler TM, Lackner J, Kiss G, Rehder P, Madersbacher H. Predictive value of initial urodynamic pattern on urinary continence in patients with myelomeningocele. Neurourol Urodyn 2006;25:361–7.
22. Madersbacher H. Development of the upper urinary tract in myelomeningocele and consequent urological care. Int Urol Nephrol 1975;7:13–22.
23. Stöhrer M, Castro-Diaz D, Chartier-Kastler E, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Neurogenic_LUTS.pdf. 2008:1–52.
24. Madersbacher H, Wyndaele JJ, Igawa Y, et al. Conservative management in neuropathic urinary incontinence. In: Abrams P, Khoury S, Wein A, eds. Incontinence. Second edn. Plymouth: Health Publications Ltd; 2002:697–754.
25. Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol 1972;107:458–61.
26. Alpert SA, Cheng EY, Zebold KF, Kaplan WE. Clean intermittent catheterization in genitally sensate children: patient experience and health related quality of life. J Urol 2005;174(4 Pt 2):1616–9.
27. Kessler TM, Ryu G, Burkhard FC. Clean intermittent self-catheterization: a burden for the patient? Neurourol Urodyn 2009;28:18–21.
28. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008;53:275–87.
29. Game X, Mouracade P, Chartier-Kastler E, et al. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol 2009;5:156–64.
30. Schulte-Baukloh H, Knispel HH, Stolze T, et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005;66:865–70.
31. Akbar M, Abel R, Seyler TM, et al. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 2007;100:639–45.
32. Joyner BD, McLorie GA, Khoury AE. Sexuality and reproductive issues in children with myelomeningocele. Eur J Pediatr Surg 1998;8:29–34.
33. Blum RW, Resnick MD, Nelson R, St Germaine A. Family and peer issues among adolescents with spina bifida and cerebral palsy. Pediatrics 1991;88:280–5.
34. Cartright DB, Joseph AS, Grenier CE. A self-image profile analysis of spina bifida adolescents in Louisiana. J La State Med Soc 1993;145:394–6, 399–402.
35. Game X, Moscovici J, Game L, et al. Evaluation of sexual function in young men with spina bifida and myelomeningocele using the International Index of Erectile Function. Urology 2006;67:566–70.
36. Lassmann J, Garibay Gonzalez F, Melchionni JB, Pasquariello PS, Jr., Snyder HM, 3rd. Sexual function in adult patients with spina bifida and its impact on quality of life. J Urol 2007;178(4 Pt 2):1611–4.
37. Verhoef M, Barf HA, Vroege JA, et al. Sex education, relationships, and sexuality in young adults with spina bifida. Arch Phys Med Rehabil 2005;86:979–87.
38. Bong GW, Rovner ES. Sexual health in adult men with spina bifida. ScientificWorldJournal 2007;7:1466–9.
39. Reilly JM, Oates RD. Preliminary investigation of the potential fertility status of postpubertal males with myelodysplasia. J Urol 1992;147(75 A (abstract 150)).
40. Glass C, Soni B. ABC of sexual health: sexual problems of disabled patients. BMJ 1999;318:518–21.
41. Palmer JS, Kaplan WE, Firlit CF. Erectile dysfunction in spina bifida is treatable. Lancet 1999;354:125–6.
42. Palmer JS, Kaplan WE, Firlit CF. Erectile dysfunction in patients with spina bifida is a treatable condition. J Urol 2000;164(3 Pt 2):958–61.
43. Overgoor ML, Kon M, Cohen-Kettenis PT, et al. Neurological bypass for sensory innervation of the penis in patients with spina bifida. J Urol 2006;176:1086–90.
44. Krogh K, Lie HR, Bilenberg N, Laurberg S. Bowel function in Danish children with myelomeningocele. APMIS Suppl 2003;(109):81–5.
45. Lie HR, Lagergren J, Rasmussen F, et al. Bowel and bladder control of children with myelomeningocele: a Nordic study. Dev Med Child Neurol 1991;33:1053–61.
46. Younoszai MK. Stooling problems in patients with myelomeningocele. South Med J 1992;85:718–24.
47. Nanigian DK, Nguyen T, Tanaka ST, et al. Development and validation of the fecal incontinence and constipation quality of life measure in children with spina bifida. J Urol 2008;180(4 Suppl):1770–3.
48. Vande Velde S, Van Biervliet S, Van Renterghem K, et al. Achieving fecal continence in patients with spina bifida: a descriptive cohort study. J Urol 2007;178:2640–4.
49. de Jong TP, Chrzan R, Klijn AJ, Dik P. Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol 2008;23:889–96.
50. Lopez Pereira P, Salvador OP, Arcas JA, et al. Transanal irrigation for the treatment of neuropathic bowel dysfunction. J Pediatr Urol 2010; 6:134–8.
51. Loening-Baucke V, Desch L, Wolraich M. Biofeedback training for patients with myelomeningocele and fecal incontinence. Dev Med Child Neurol 1988;30:781–90.
52. Palmer LS, Richards I, Kaplan WE. Transrectal electrostimulation therapy for neuropathic bowel dysfunction in children with myelomeningocele. J Urol 1997;157:1449–52.
53. Han SW, Kim MJ, Kim JH, et al. Intravesical electrical stimulation improves neurogenic bowel dysfunction in children with spina bifida. J Urol 2004;171(6 Pt 2):2648–50.
54. Malone PS, Ransley PG, Kiely EM. Preliminary report: the antegrade continence enema. Lancet 1990;336:1217–8.
55. Bani-Hani AH, Cain MP, King S, Rink RC. Tap water irrigation and additives to optimize success with the Malone antegrade continence enema: the Indiana University algorithm. J Urol 2008;180(4 Suppl):1757–60.
56. Aksnes G, Diseth TH, Helseth A, et al. Appendicostomy for antegrade enema: effects on somatic and psychosocial functioning in children with myelomeningocele. Pediatrics 2002;109:484–9.
57. Mowatt G, Glazener C, Jarrett M.Sacral nerve stimulation for faecal incontinence and constipation in adults. Cochrane Database Syst Rev 2007(3):CD004464.
58. Yamada S, Won DJ, Yamada SM. Pathophysiology of tethered cord syndrome: correlation with symptomatology. Neurosurg Focus 2004;16(2):E6.
59. Brezner A, Kay B. Spinal cord ultrasonography in children with myelomeningocele. Dev Med Child Neurol 1999;41:450–5.
60. Phuong LK, Schoeberl KA, Raffel C. Natural history of tethered cord in patients with meningomyelocele. Neurosurgery 2002;50:989–93.
61. Bowman RM, Mohan A, Ito J, Seibly JM, McLone DG. Tethered cord release: a long-term study in 114 patients. J Neurosurg Pediatr 2009;3:181–7.
62. Dias MS, McLone DG. Hydrocephalus in the child with dysraphism. Neurosurg Clin N Am 1993;4:715–26.
63. Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg 2001;34:114–20.
64. Tomita T, McLone DG. Acute respiratory arrest. A complication of malformation of the shunt in children with myelomeningocele and Arnold-Chiari malformation. Am J Dis Child 1983;137:142–4.
65. Giddens JL, Radomski SB, Hirshberg ED, Hassouna M, Fehlings M. Urodynamic findings in adults with the tethered cord syndrome. J Urol 1999;161:1249–54.
66. Meyrat BJ, Vernet O, Berger D, de Tribolet N. Pre- and postoperative urodynamic and anorectal manometric findings in children operated upon for a primary tethered cord. Eur J Pediatr Surg 1993;3:309–12.
67. Kayaba H, Hebiguchi T, Itoh Y, et al. Evaluation of anorectal function in patients with tethered cord syndrome: saline enema test and fecoflowmetry. J Neurosurg 2003;98(3 Suppl):251–7.

References

1. Podnar S. Saddle sensation is preserved in a few patients with cauda equina or conus medullaris lesions. Eur J Neurol 2007;14:48–53.
2. Brindley GS. The Ferrier lecture, 1986. The actions of parasympathetic and sympathetic nerves in human micturition, erection and seminal emission, and their restoration in paraplegic patients by implanted electrical stimulators. Proc R Soc Lond B Biol Sci 1988;235:111–20.
3. Hauck EF, Wittkowski W, Bothe HW. Intradural microanatomy of the nerve roots S1-S5 at their origin from the conus medullaris. J Neurosurg Spine 2008;9:207–12.
4. Podnar S. Epidemiology of cauda equina and conus medullaris lesions. Muscle Nerve 2007;35:529–31.
5. Gitelman A, Hishmeh S, Morelli BN, et al. Cauda equina syndrome: a comprehensive review. Am J Orthop 2008;37:556–62.
6. Lavy C, James A, Wilson-MacDonald J, Fairbank J. Cauda equina syndrome. BMJ 2009;338:b936
7. Jensen RL. Cauda equina syndrome as a postoperative complication of lumbar spine surgery. Neurosurg Focus 2004;16:e7.
8. Podnar S. Cauda equina lesions as a complication of spinal surgery. Eur Spine J 2010;19:451–7.
9. Aldrete JA. Neurologic deficits and arachnoiditis following neuroaxial anesthesia. Acta Anaesthesiol Scand 2003;47:3–12.
10. Cook TM, Counsell D, Wildsmith JA. Major complications of central neuraxial block: report on the Third National Audit Project of the Royal College of Anaesthetists. Br J Anaesth 2009;102:179–90.
11. Loo CC, Irestedt L. Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993–1997. Acta Anaesthesiol Scand 1999;43:371–9.
12. Bagley CA, Gokaslan ZL. Cauda equina syndrome caused by primary and metastatic neoplasms. Neurosurg Focus 2004;16:e3.
13. Moon MS. Tuberculosis of the spine. Controversies and a new challenge. Spine (Phila Pa 1976) 1997;22:1791–7.
14. Hopkins A, Clarke C, Brindley G. Erections on walking as a symptom of spinal canal stenosis. J Neurol Neurosurg Psychiatry 1987;50:1371–4.
15. Sakakibara R, Yamamoto T, Uchiyama T, et al. Is lumbar spondylosis a cause of urinary retention in elderly women? J Neurol 2005;252:953–7.
16. Bartelson JD, Cohen MD, Harrington TM. Cauda equina syndrome secondary to long-standing ankylosing spondylitis. Ann Neurol 1983;14:662–8.
17. Hassan I. Cauda equina syndrome in ankylosing spondylitis: a report of six cases. J Neurol Neurosurg Psychiatry 1976;39:1172–8.
18. Aminoff M, Logue V. Clinical features of spinal vascular malformations. Brain 1974;97:197–210.
19. DeLong WB, Polissar N, Neradilek B. Timing of surgery in cauda equina syndrome with urinary retention: meta-analysis of observational studies. J Neurosurg Spine 2008;8:305–20.
20. Jalloh I, Minhas P. Delays in the treatment of cauda equina syndrome due to its variable clinical features in patients presenting to the emergency department. Emerg Med J 2007;24:33–4.
21. Kostuik JP. Medicolegal consequences of cauda equina syndrome: an overview. Neurosurg Focus 2004;16:e8.
22. Bell DA, Collie D, Statham PF. Cauda equina syndrome: what is the correlation between clinical assessment and MRI scanning? Br J Neurosurg 2007;21:201–3.
23. Rooney A, Statham PF, Stone J. Cauda equina syndrome with normal MR imaging. J Neurol 2009;256:721–5.
24. Fowler TJ, Danta G, Gilliatt RW. Recovery of nerve conduction after a pneumatic tourniquet: observations on the hind-limb of the baboon. J Neurol Neurosurg Psychiatry 1972;35:638–47.
25. Podnar S, Trsinar B, Vodusek DB. Bladder dysfunction in patients with cauda equina lesions. Neurourol Urodyn 2006;25:23–31.
26. Bors E. Neurogenic bladder. Urol Surv 1957;7:177–250.
27. Dixon JS, Jen PY, Gosling JA. The distribution of vesicular acetylcholine transporter in the human male genitourinary organs and its co-localization with neuropeptide Y and nitric oxide synthase. Neurourol Urodyn 2000;19:185–94.
28. de Groat WC, Kawatani M. Reorganization of sympathetic preganglionic connections in cat bladder ganglia following parasympathetic denervation. J Physiol 1989;409:431–49.
29. Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in conus medullaris and cauda equina injury. Arch Neurol 1983;40:570–3.
30. Hellstrom P, Kortelainen P, Kontturi M. Late urodynamic findings after surgery for cauda equina syndrome caused by a prolapsed lumbar intervertebral disk. J Urol 1986;135:308–12.
31. Fowler CJ. Neurological disorders of micturition and their treatment. Brain 1999;122:1213–31.
32. Hattori T, Yasuda K, Sakakibara R, et al. Micturitional disturbance in tumors of the lumbosacral area. J Spinal Disord 1992;5:193–7.
33. Podnar S. Bowel dysfunction in patients with cauda equina lesions. Eur J Neurol 2006;13:1112–7.
34. Podnar S, Oblak C, Vodusek DB. Sexual function in men with cauda equina lesions: a clinical and electromyographic study. J Neurol Neurosurg Psychiatry 2002;73:715–20.
35. Sipski ML, Alexander CJ, Rosen R. Sexual arousal and orgasm in women: effects of spinal cord injury. Ann Neurol 2001;49:35–44.
36. Shapiro S. Cauda equina syndrome secondary to lumbar disc herniation. Neurosurgery 1993;32:743–6.
37. Kennedy JG, Soffe KE, McGrath A, et al. Predictors of outcome in cauda equina syndrome. Eur Spine J 1999;8:317–22.

References

1. Llewelyn J, Tomlinson D, Thomas P. Diabetic neuropathies. In: Dyck P, Thomas P, eds. Peripheral neuropathy. Fourth edn. Philadelphia: Elsevier Saunders; 2005:1951–92.
2. Jordan W. Neuritic manifestations in diabetes mellitus. Arch Intern Med 1936;57:307–366.
3. Frimodt-Moller C. Diabetic cystopathy: epidemiology and related disorders. Ann Intern Med 1980;92(2 Pt 2):318–21.
4. Frimodt-Moller C, Mortensen S. Treatment of diabetic cystopathy. Ann Intern Med 1980;92(2 Pt 2):327–8.
5. Lifford KL, Curhan GC, Hu FB, Barbieri RL, Grodstein F. Type 2 diabetes mellitus and risk of developing urinary incontinence. J Am Geriatr Soc 2005;53:1851–7.
6. Hill SR, Fayyad AM, Jones GR. Diabetes mellitus and female lower urinary tract symptoms: a review. Neurourol Urodyn 2008;27:362–7.
7. Van Poppel H, Stessens R, Van Damme B, Carton H, Baert L. Diabetic cystopathy: neuropathological examination of urinary bladder biopsies. Eur Urol 1988;15:128–31.
8. Sasaki K, Chancellor MB, Phelan MW, et al. Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root ganglia. J Urol 2002;168:1259–64.
9. Yoshimura N, Chancellor MB, Andersson KE, Christ GJ. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int 2005;95:733–8.
10. Longhurst PA, Belis JA. Abnormalities of rat bladder contractility in streptozotocin-induced diabetes mellitus. J Pharmacol Exp Ther 1986;238:773–7.
11. Yamaguchi C, Sakakibara R, Uchiyama T, et al. Overactive bladder in diabetes: a peripheral or central mechanism? Neurourol Urodyn 2007;26:807–13.
12. Fayyad AM, Hill SR, Jones G. Prevalence and risk factors for bothersome lower urinary tract symptoms in women with diabetes mellitus from hospital-based diabetes clinic. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:1339–44.
13. Fayyad AM, Hill SR, Jones G. Urine production and bladder diary measurements in women with type 2 diabetes mellitus and their relation to lower urinary tract symptoms and voiding dysfunction. Neurourol Urodyn 2010;29:354–8.
14. Jackson RA, Vittinghoff E, Kanaya AM, et al. Urinary incontinence in elderly women: findings from the Health, Aging, and Body Composition Study. Obstet Gynecol 2004;104:301–7.
15. Kaplan SA, Te AE, Blaivas JG. Urodynamic findings in patients with diabetic cystopathy. J Urol 1995;153:342–4.
16. Ueda T, Yoshimura N, Yoshida O. Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response. J Urol 1997;157:580–4.
17. Vinik A, Richardson D. Erectile dysfunction in diabetes. Diabetes Rev 1998;6:16–33.
18. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61.
19. Awad H, Salem A, Gadalla A, El Wafa NA, Mohamed OA. Erectile function in men with diabetes type 2: correlation with glycemic control. Int J Impot Res 2010;22:36–9.
20. Hermans MP, Ahn SA, Rousseau MF. Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes. Diabetes Metab 2009;35:484–9.
21. Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007(1):CD002187.
22. Erol B, Tefekli A, Ozbey I, et al. Sexual dysfunction in type II diabetic females: a comparative study. J Sex Marital Ther 2002;28(Suppl 1):55–62.
23. Fatemi SS, Taghavi SM. Evaluation of sexual function in women with type 2 diabetes mellitus. Diab Vasc Dis Res 2009;6:38–9.
24. Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32:151–9.
25. Ziegler D, Schadewaldt P, Pour Mirza A, et al. [13C]octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia 1996;39:823–30.
26. Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 1996;19:468–71.
27. Ko GT, Chan WB, Chan JC, Tsang LW, Cockram CS. Gastrointestinal symptoms in Chinese patients with Type 2 diabetes mellitus. Diabet Med 1999;16:670–4.
28. Enck P, Rathmann W, Spiekermann M, et al. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol 1994;32:637–41.
29. Schvarcz E, Palmer M, Ingberg CM, Aman J, Berne C. Increased prevalence of upper gastrointestinal symptoms in long-term type 1 diabetes mellitus. Diabet Med 1996;13:478–81.
30. Caruana BJ, Wald A, Hinds JP, Eidelman BH. Anorectal sensory and motor function in neurogenic fecal incontinence. Comparison between multiple sclerosis and diabetes mellitus. Gastroenterology 1991;100:465–70.
31. Russo A, Botten R, Kong MF, et al. Effects of acute hyperglycaemia on anorectal motor and sensory function in diabetes mellitus. Diabet Med 2004;21:176–82.
32. Zochodne DW. Autonomic involvement in Guillain-Barre syndrome: a review. Muscle Nerve 1994;17:1145–55.
33. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005;366:1653–66.
34. Sakakibara R, Uchiyama T, Kuwabara S, et al. Prevalence and mechanism of bladder dysfunction in Guillain-Barre Syndrome. Neurourol Urodyn 2009;28:432–7.
35. Muller HD, Beckmann A, Schroder JM. Inflammatory infiltrates in the spinal cord of patients with Guillain-Barre syndrome. Acta Neuropathol 2003;106:509–17.
36. Burk K, Weiss A. Impotence after recovery from Guillain-Barre syndrome. N J Med 1998;95:31–4.
37. Burns TM, Lawn ND, Low PA, Camilleri M, Wijdicks EF. Adynamic ileus in severe Guillain-Barre syndrome. Muscle Nerve 2001;24:963–5.
38. Sakakibara R, Uchiyama T, Asahina M, et al. Micturition disturbance in acute idiopathic autonomic neuropathy. J Neurol Neurosurg Psychiatry 2004;75:287–91.
39. Gibbons CH, Freeman R. Antibody titers predict clinical features of autoimmune autonomic ganglionopathy. Auton Neurosci 2009;146:8–12.
40. Kaufmann H, Hague K, Perl D. Accumulation of alpha-synuclein in autonomic nerves in pure autonomic failure. Neurology 2001;56:980–1.
41. Sakakibara R, Hattori T, Uchiyama T, Asahina M, Yamanishi T. Micturitional disturbance in pure autonomic failure. Neurology 2000;54:499–501.
42. Thomas P. Pelvic plexus injury. In: Mundy A, Stephenson T, Wein A, eds. Urodynamics, principles, practice and application. Edinburgh: Churchill Livingstone; 1994.
43. Dixon JS, Gilpin SA, Gilpin CJ, Gosling JA. Intramural ganglia of the human urinary bladder. Br J Urol 1983;55:195–8.
44. Staskin DR, Parsons KF, Levin RM, Wein AJ. Bladder transection – a functional, neurophysiological, neuropharmacological and neuroanatomical study. Br J Urol 1981;53:552–7.
45. Rees PM, Fowler CJ, Maas CP. Sexual function in men and women with neurological disorders. Lancet 2007;369:512–25.
46. Artman LE, Hoskins WJ, Bibro MC, et al. Radical hysterectomy and pelvic lymphadenectomy for stage IB carcinoma of the cervix: 21 years experience. Gynecol Oncol 1987;28:8–13.
47. Chuang TY, Yu KJ, Penn IW, et al. Neurourological changes before and after radical hysterectomy in patients with cervical cancer. Acta Obstet Gynecol Scand 2003;82:954–9.
48. Everaert K, De Muynck M, Rimbaut S, Weyers S. Urinary retention after hysterectomy for benign disease: extended diagnostic evaluation and treatment with sacral nerve stimulation. BJU Int 2003;91:497–501.
49. Brooks RA, Wright JD, Powell MA, et al. Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. Gynecol Oncol 2009;114:75–9.
50. Maas CP, ter Kuile MM, Laan E, et al. Objective assessment of sexual arousal in women with a history of hysterectomy. BJOG 2004;111:456–62.
51. Pieterse QD, Maas CP, ter Kuile MM, et al. An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. Int J Gynecol Cancer 2006;16:1119–29.
52. Jensen PT, Groenvold M, Klee MC, et al. Early-stage cervical carcinoma, radical hysterectomy, and sexual function. A longitudinal study. Cancer 2004;100:97–106.
53. Dursun P, Ayhan A, Kuscu E. Nerve-sparing radical hysterectomy for cervical carcinoma. Crit Rev Oncol Hematol 2009;70:195–205.
54. Pieterse QD, Ter Kuile MM, Deruiter MC, et al. Vaginal blood flow after radical hysterectomy with and without nerve sparing. A preliminary report. Int J Gynecol Cancer 2008;18:576–83.
55. Zippe CD, Raina R, Shah AD, et al. Female sexual dysfunction after radical cystectomy: a new outcome measure. Urology 2004;63:1153–7.
56. Kessler TM, Burkhard FC, Studer UE. Clinical indications and outcomes with nerve-sparing cystectomy in patients with bladder cancer. Urol Clin North Am 2005;32:165–75.
57. Lange MM, Marijnen CA, Maas CP, et al. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer 2009;45:1578–88.
58. Pocard M, Zinzindohoue F, Haab F, et al. A prospective study of sexual and urinary function before and after total mesorectal excision with autonomic nerve preservation for rectal cancer. Surgery 2002;131:368–72.
59. Cohen BA, McArthur JC, Grohman S, Patterson B, Glass JD. Neurologic prognosis of cytomegalovirus polyradiculomyelopathy in AIDS. Neurology 1993;43(3 Pt 1):493–9.
60. Gyrtrup HJ, Kristiansen VB, Zachariae CO, et al. Voiding problems in patients with HIV infection and AIDS. Scand J Urol Nephrol 1995;29:295–8.
61. Garber SJ, Christmas TJ, Rickards D. Voiding dysfunction due to neurosyphilis. Br J Urol 1990;66:19–21.
62. Hattori T, Yasuda K, Kita K, Hirayama K. Disorders of micturition in tabes dorsalis. Br J Urol 1990;65:497–9.
63. Lefaucheur JP, Labat JJ, Amarenco G, et al. What is the place of electroneuromyographic studies in the diagnosis and management of pudendal neuralgia related to entrapment syndrome? Neurophysiol Clin 2007;37:223–8.
64. Stav K, Dwyer PL, Roberts L. Pudendal neuralgia. Fact or fiction? Obstet Gynecol Surv 2009;64:190–9.
65. Labat JJ, Riant T, Robert R, et al. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). Neurourol Urodyn 2008;27:306–10.
66. Popeney C, Ansell V, Renney K. Pudendal entrapment as an etiology of chronic perineal pain: diagnosis and treatment. Neurourol Urodyn 2007;26:820–7.
67. Filler AG. Diagnosis and treatment of pudendal nerve entrapment syndrome subtypes: imaging, injections, and minimal access surgery. Neurosurg Focus 2009;26:E9.
68. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64–71.
69. Andrade MJ. Lower urinary tract dysfunction in familial amyloidotic polyneuropathy, Portuguese type. Neurourol Urodyn 2009;28:26–32.
70. Denier C, Ducot B, Husson H, et al. A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy. J Neurol 2007;254:1684–8.
71. Lobato L. Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M). J Nephrol 2003;16:438–42.
72. Ito T, Sakakibara R, Ito S, et al. Mechanism of constipation in familial amyloid polyneuropathy: a case report. Intern Med 2006;45:1173–5.
73. Obayashi K, Ando Y, Terazaki H, et al. Effect of sildenafil citrate (Viagra) on erectile dysfunction in a patient with familial amyloidotic polyneuropathy ATTR Val30Met. J Auton Nerv Syst 2000;80:89–92.
74. Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123(Pt 7):1495–504.
75. Holmgren G, Lundgren HE, Suhr OB. Successful pregnancies and fatherhood in familial amyloidotic polyneuropathy (FAP Val30Met) patients with liver transplantation. Amyloid 2004;11:125–9.
76. Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 2004;17:615–20.
77. Saini J, Axelrod FB, Maayan C, Stringer J, Smilen SW. Urinary incontinence in familial dysautonomia. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:209–13.
78. Axelrod FB. Familial dysautonomia. Muscle Nerve 2004;29:352–63.
79. Miura S, Shibata H, Kida H, et al. Hereditary motor and sensory neuropathy with proximal dominancy in the lower extremities, urinary disturbance, and paroxysmal dry cough. J Neurol Sci 2008;273:88–92.
80. Vinci P, Gargiulo P, Navarro-Cremades F. Sexuality in Charcot-Marie-Tooth disease. Eura Medicophys 2007;43:295–6.
81. Bird TD, Lipe HP, Crabtree LD. Impotence associated with the Charcot-Marie-Tooth syndrome. Eur Neurol 1994;34:155–7.
82. Waterman SA. Autonomic dysfunction in Lambert-Eaton myasthenic syndrome. Clin Auton Res 2001;11:145–54.
83. Sandler PM, Avillo C, Kaplan SA. Detrusor areflexia in a patient with myasthenia gravis. Int J Urol 1998;5:188–90.
84. Kaya C, Karaman MI. Case report: a case of bladder dysfunction due to myasthenia gravis. Int Urol Nephrol 2005;37:253–5.
85. Vernino S, Cheshire WP, Lennon VA. Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci 2001;88:187–92.
86. British National Formulary [online]. Available from: http://bnf.org/bnf/[accessed 8 Sept 2009].
87. MacLeod M, Kelly R, Robb SA, Borzyskowski M. Bladder dysfunction in Duchenne muscular dystrophy. Arch Dis Child 2003;88:347–9.
88. Caress JB, Kothari MJ, Bauer SB, Shefner JM. Urinary dysfunction in Duchenne muscular dystrophy. Muscle Nerve 1996;19:819–22.
89. Abercrombie JF, Rogers J, Swash M. Faecal incontinence in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1998;64:128–30.
90. Pelliccioni G, Scarpino O, Piloni V. Procainamide for faecal incontinence in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1999;67:257–8.
91. Sakakibara R, Hattori T, Tojo M, et al. Micturitional disturbance in myotonic dystrophy. J Auton Nerv Syst 1995;52:17–21.
92. Antonini G, Clemenzi A, Bucci E, et al. Erectile dysfunction in myotonic dystrophy type 1 (DM1). J Neurol 2009;256:657–9.
93. Nishino I, Spinazzola A, Papadimitriou A, et al. Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 2000;47:792–800.
94. Barrett TG, Bundey SE. Wolfram (DIDMOAD) syndrome. J Med Genet 1997;34:838–41.
95. Haftel LT, Lev D, Barash V, et al. Familial mitochondrial intestinal pseudo-obstruction and neurogenic bladder. J Child Neurol 2000;15:386–9.

References

1. Hahn K, Ebersbach G. Sonographic assessment of urinary retention in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 2005;20:1499–502.
2. Ito T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 2006;21:816–23.
3. Lapointe SP, Rivet C, Goulet O, Fekete CN, Lortat-Jacob S. Urological manifestations associated with chronic intestinal pseudo-obstructions in children. J Urol 2002;168(4 Pt 2):1768–70.
4. Mousa H, Hyman PE, Cocjin J, Flores AF, Di Lorenzo C. Long-term outcome of congenital intestinal pseudoobstruction. Dig Dis Sci 2002;47:2298–305.
5. Vargas JH, Sachs P, Ament ME. Chronic intestinal pseudo-obstruction syndrome in pediatrics. Results of a national survey by members of the North American Society of Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1988;7:323–32.
6. Wiseman OJ, Fowler CJ, Landon DN. The role of the human bladder lamina propria myofibroblast. BJU Int 2003;91:89–93.
7. Knox S. Psychogenic urinary retention after parturition resulting in hydronephrosis. Br Med J 1960;2:1422–4.
8. Margolis GJ. A review of literature on psychogenic urinary retention. J Urol 1965;94:257–8.
9. Allen TD. Psychogenic urinary retention. South Med J 1972;65:302–4.
10. Barrett DM. Psychogenic urinary retention in women. Mayo Clin Proc 1976;51:351–6.
11. Montague DK, Jones LR. Psychogenic urinary retention. Urol 1979;13:30–5.
12. Bird JR. Psychogenic urinary retention. Psychother Psychosom 1980;34:45–51.
13. Bassi P, Zattoni F, Aragona F, et al. La retention psychogene d'urine chez la femme: aspects diagnostiques et therapeutiques. J d'Urologie 1988;94:159–62.
14. Moore T. Bladder-neck obstruction in women. Proc R Soc Med 1953;46:558–64.
15. Raz S, Smith RB. External sphincter spasticity syndrome in female patients. J Urol 1976;115:443–6.
16. Fowler CJ, Kirby RS. Abnormal electromyographic activity (decelerating bursts and complex repetitive discharges) in the striated muscle of the urethral sphincter in 5 women with persisting urinary retention. Br J Urol 1985;57:69–70.
17. Fowler CJ, Christmas TJ, Chapple CR, et al. Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome? BMJ 1988;297:1436–8.
18. Fowler CJ, Kirby RS, Harrison MJ. Decelerating burst and complex repetitive discharges in the striated muscle of the urethral sphincter, associated with urinary retention in women. J Neurol Neurosurg Psychiatry 1985;48:1004–9.
19. Butler WJ. Pseudomyotonia of the periurethral sphincter in women with urinary incontinence. J Urol 1979;122:838–40.
20. Jensen D, Stien R . The importance of complex repetitive discharges in the striated female urethral sphincter and male bulbocavernosus muscle. Scand J Urol Nephrol Suppl 1996;179:69–73.
21. FitzGerald MP, Blazek B, Brubaker L. Complex repetitive discharges during urethral sphincter EMG: clinical correlates. Neurourol Urodyn 2000;19:577–83.
22. Fowler CJ, Dasgupta R. Electromyography in urinary retention and obstructed voiding in women. Scand J Urol Nephrol Suppl 2002:55–8.
23. O'Connell HE, Hutson JM, Anderson CR, Plenter RJ. Anatomical relationship between urethra and clitoris. J Urol 1998;159:1892–7.
24. O'Connell HE, DeLancey JO. Clitoral anatomy in nulliparous, healthy, premenopausal volunteers using unenhanced magnetic resonance imaging. J Urol 2005;173:2060–3.
25. Swinn MJ, Wiseman O, Lowe E, Fowler CJ. The cause and natural history of isolated urinary retention in young women. J Urol 2002;167:151–6.
26. Wiseman OJ, Swinn MJ, Brady CM, Fowler CJ. Maximum urethral closure pressure and sphincter volume in women with urinary retention. J Urol 2002;167:1348–51.
27. Edwards L, Malvern J. The urethral pressure profile: theoretical considerations and clinical application. Br J Urol 1974;46:325–36.
28. Wiseman OJ, Swinn MJ, Brady CM, Fowler CJ. Maximum urethral closure pressure and sphincter volume in women in retention. J Urol 2002;167:367–71.
29. de Groat WC, Fraser MO, Yoshiyama M, et al. Neural control of the urethra. Scand J Urol Nephrol Suppl 2001;35:35–43.
30. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453–66.
31. Kavia R, Dasgupta R, Critchley H, Fowler C, Griffiths D. A functional magnetic resonance imaging study of the effect of sacral neuromodulation on brain responses in women with Fowler's syndrome. BJU Int 2010;105:366–72.
32. Swinn MJ, Kitchen ND, Goodwin RJ, Fowler CJ. Sacral neuromodulation for women with Fowler's syndrome. Eur Urol 2000;38:439–43.
33. DasGupta R, Fowler CJ. Urodynamic study of women in urinary retention treated with sacral neuromodulation. J Urol 2004;171:1161–4.
34. Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol 2005;174:2268–72.
35. Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf 2008;31:373–88.
36. Malinovsky JM, Le Normand L, Lepage JY, et al. The urodynamic effects of intravenous opioids and ketoprofen in humans. Anesth Analg 1998;87:456–61.
37. Kuipers PW, Kamphuis ET, van Venrooij GE, et al. Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. Anesthesiology 2004;100:1497–503.
38. Petros JG, Realica R, Ahmad S, Rimm EB, Robillard RJ. Patient-controlled analgesia and prolonged ileus after uncomplicated colectomy. Am J Surg 1995;170:371–4.
39. Pandita RK, Pehrson R, Christoph T, Friderichs E, Andersson KE. Actions of tramadol on micturition in awake, freely moving rats. Br J Pharmacol 2003;139:741–8.
40. Pehrson R, Andersson KE. Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation. J Urol 2003;170:272–5.
41. Meyboom RH, Brodie-Meijer CC, Diemont WL, van Puijenbroek EP. Bladder dysfunction during the use of tramadol. Pharmacoepidemiol Drug Saf 1999;8(Suppl 1):S63–4.
42. Matsumoto S, Levendusky MC, Longhurst PA, Levin RM, Millington WR. Activation of mu opioid receptors in the ventrolateral periaqueductal gray inhibits reflex micturition in anesthetized rats. Neurosci Lett 2004;363:116–9.
43. Panicker J, Khan S, Kessler T, et al. The possible role of opiates in women with urinary retention. Observations from a prospective clinical study. 39th Annual Meeting of the International Continence Society (ICS). San Francisco; 2009.
44. Datta SN, Chaliha C, Singh A, et al. Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. BJU Int 2008;101:192–6.
45. Van Voskuilen AC, Oerlemans DJ, Weil EH, van den Hombergh U, van Kerrebroeck PE. Medium-term experience of sacral neuromodulation by tined lead implantation. BJU Int 2007;99:107–10.
46. Elhilali MM, Khaled SM, Kashiwabara T, Elzayat E, Corcos J. Sacral neuromodulation: long-term experience of one center. Urology 2005;65:1114–7.
47. De Ridder D, Ost D, Bruyninckx F. The presence of Fowler's syndrome predicts successful long-term outcome of sacral nerve stimulation in women with urinary retention. Eur Urol 2007;51:229–33.
48. Elneil S, Khan S, Kavia RBCet al. Two-stage sacral neuromodulation for chronic urinary retention in women: outcome and response prognostic factors. In prepration.
49. Chen ML, Shen B, Wang Jet al. Influence of naloxone on inhibitory predendal-to-bladder reflex in cats. Exp Neurol 2010;224:282–91.
50. Datta SN, Kavia RB, Gonzales G, Fowler CJ. Results of double-blind placebo-controlled crossover study of sildenafil citrate (Viagra) in women suffering from obstructed voiding or retention associated with the primary disorder of sphincter relaxation (Fowler's syndrome). Eur Urol 2007;51:489–97.
51. Fowler CJ, Betts CD, Christmas TJ, Swash M, Fowler CG. Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol 1992;70:387–9.
52. Jonas U, Fowler CJ, Chancellor MB, et al. Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol 2001;165:15–9.